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1 Summary 
1.1 English 
 
An important initial step towards cervical cancer is the integration of HPV DNA 
copies into the host genome. Subsequently, the viral DNA gets targeted by methylation 
leading to its transcriptional silencing (Jeon et al., 1995; Yu et al., 2005). Later on, 
demethylation of these inserted HPV genomes correlates with further progression of cervical 
cancer (Badal et al., 2003). Therefore, characterisation of epigenetic mechanisms involved in 
oncogene re-expression is required to potentially counteract cancer development. 
In this study, the contribution of both epigenetic mechanisms, DNA demethylation and 
incorporation of histone variant H3.3 for the re-activation of the viral DNA transcription was 
analyzed. The cervical cancer cell line CaSki harbors approximately 600 mostly methylated 
HPV-16 copies and provides an excellent in vitro model to study epigenetic mechanisms in 
the context of HPV induced carcinogenesis. DNA demethylation was induced by treatment of 
these cells with 5-Azacytidine (DAC), which led to demethylation of approximately 50% of 
the silent HPV-16 copies. In addition, clones stably expressing a Myc-tagged H3.3 were 
generated and characterized in combination with DAC treatment. 
On protein level, DAC treatment of CaSki cells was accompanied by an unexpected 
down-regulation of the oncoprotein E7, where intracellular half life was rescued after 
exposure to proteosomal and calpain inhibitors. Additionally, for the first time, an interaction 
of E7 with, the transcription activating histone arginine methyltransferase, CARM1 was 
detected after E7-IP by Mass Spectrometry and Western blot. On transcriptional level, a 
slightly down-regulation of the E7 oncogene was detectable after DAC treatment of CaSki 
cells. Importantly, the same treatment induced E7 transcription in CaSki clones expressing 
Myc-H3.3, which was verified by both qPCR and Northern blot. 
 In summary, this study demonstrates that DAC treatment induces down-regulation of 
oncoprotein E7 in CaSki cells. In addition, the data imply that DNA demethylation alone is 
not sufficient for re-activation of silent HPV genomes, since induction of E7 transcription 
strictly requires both, DNA demethylation and incorporation of the histone variant H3.3 into 
the URR of HPV-16.  
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1.2 German: Zusammenfassung 
Das Cervixcarzinom ist die zweithäufigste malignombedingte Todesursache bei 
Frauen weltweit. Pathogenetisch kommt dabei der Integration humaner Papillomviren (HPV) 
in das Genom ihrer Wirtszellen eine entscheidende Rolle zu (Jeon et al., 1995; Yu et al., 
2005). Anschließend erfolgt die Methylierung der meisten integrierten viralen Genome, wobei 
die Transkription viraler Onkogene durch einige nicht-methylierte Kopien noch gewährleistet 
bleibt. Im Rahmen der weiteren Krankheitsprogression werden Anteile der zunächst 
methylierten viralen DNA dann erneut demethyliert (Badal et al., 2001). Die genaue 
Entschlüsselung des Zusammenwirkens dieser epigenetischen Mechanismen, deren 
Interaktionen zur Reaktivierung ausgeschalteter Genome führt, ist daher zum Verständnis der 
Entstehung und Progression des Cervixcarzinoms von entscheidender Bedeutung. 
In der vorliegenden Arbeit wird die Rolle der epigenetischen Mechanismen, DNA-
Methylierung und Einbau des Histon Varianten H3.3 bei der Reaktivierung von HPV-16 
DNA untersucht. Dabei wurde als optimales in vitro Model die Zervixkarzinomzelllinie 
CaSki ausgewählt. CaSki Zellen beinhalten ca. 600 integrierte und überwiegend methylierte 
HPV-16 Genome (Mincheva et al, 1987). Die Demethylierung von ca 50% der viralen DNA-
Kopien wurde durch Behandlung mit 5-Desoxy-Azacytidin (DAC) erreicht. Zusätzlich 
wurden CaSki Klone hergestellt, die den Histone 3.3 Varianten stabil exprimieren. 
Anschließende Untersuchungen ergaben, dass auf Proteinebene die Behandlung mit 
DAC zur Herunterregulation des Onkoproteins E7 führt. Inkubation mit Calpain- und 
Proteasom-Inhibitoren führte zur Hemmung der E7 Degradation in den DAC behandelten 
Proben. Zusätzlich wurde die Interaktion von E7 mit der Histone-Methyltransferase CARM1 
mittels Immunpräzipitation und anschließender Massenspektrometrie und Western Blot nach-
gewiesen. Auf transkriptioneller Ebene wurde eine leichte Herunterregulation der E7 mRNA 
in CaSki Zellen nach DAC Behandlung detektiert. Hingegen erfolgte bei gleicher 
Behandlung, in den H3.3 stabilen CaSki Klonen, der Einbau des H3.3 Varianten in der 
regulatorischen Region (URR) des HPV-16 und damit die Induktion der E7 mRNA 
Transkription. Dies konnte mittels Chromatin-Immunpräzipitation und Northern Blot 
detektiert werden. 
Zusammenfassend konnte gezeigt werden, dass die Behandlung mit DAC zur 
Herunterregulation von E7 in CaSki Zellen führt. Zusätzlich wurde nachgewiesen, dass zur 
erneuten Induktion der E7 Transkription aus ausgeschalteten HPV Genomen, neben DNA 
Demethylierung der Einbau der Histon Varianten H3.3 zwingend notwendig ist. 
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2 Introduction 
2.1 Human papilloma viruses (HPV) induced cervical cancer 
 
Cervical cancer is the second most common cancer among women worldwide (Parkin and 
Bray, 2006) and the fifth leading cause of cancer mortality. Worldwide, approximately 
470,000 new cases of cervical cancer are diagnosed annually, appearing usually among 
woman with a mean age of 52 years (Pagliusi, World Health Organisation; Fehrmann and 
Laimins, 2003).  
Persistent and long-lasting infection with one of the 15 high risk human papilloma viruses 
(HPV) is the necessary cause for development of cervical cancer (Pisani et al., 2002). In 95% 
of cervical tumors high risk HPV DNA is detectable. The most common oncogenic HPVs are 
HPV-16 and HPV-18, known to cause approximately 70% of cervical cancers (Munoz et al., 
2003). HPV is a common sexually transmitted virus. Young and middle aged healthy women 
usually undergo only transient infections, which are cleared by the immune system (Wallin et 
al., 1999; Snijders et al., 2006). Nevertheless, a small proportion of women unable to 
overcome the infection are committed to finally developing cancer. Additional risk factors are 
immuno-suppression, cigarette smoking, changing sexual partners and co-infection with the 
human immunodeficiency virus (HIV) (Waggoner, 2003; Castle et al., 2004; Hellberg et al., 
2005).  
Cervical cancer development is divided into well defined pre-malignant stages, which 
are recognized by cytological examinations of exfoliated cervical cells (zur Hausen, 2002). 
The “Pap test” was first described by Papanicolaou and is still the key diagnostic tool for 
cervical cancer screening. Abnormalities detected by Pap smears are further analysed by 
histological examination of cervical material and detection of viral DNA by PCR (Saslow et 
al., 2007). Pre-malignant stages are characterized as different cervical intraepithelial 
neoplasias ranging from CIN1 (mild dysplasia) to CIN2 (moderate dysplasia) and to CIN3 
(severe dysplasia/ carcinoma in situ) (Waggoner et al., 2003; Saslow et al., 2007). 
Prevention of cervical cancer in developed countries is based on well established and 
extended cancer screening programs, leading to a notable decrease (zur Hausen, 2002). 
Another promising approach is the population based prophylactic immunization program with 
bivalent HPV (types 16 and 18) and quadrivalent HPV (types 6, 11, 16 and 18) vaccines 
which started in 2006 (Schiller and Davies, 2004, Lowy and Schiller, 2006, Garcia and 
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Saslow; 2007). Nevertheless, despite these ambitious approaches for prevention, cervical 
cancer is still not curable. Therefore, further research for better understanding the oncogenic 
properties of high risk HPV and subsequently curing cervical cancer needs to be done. 
 
2.2 The PV genome structure and transcriptional control  
 
 Papilloma viruses (PV) are small non-enveloped double stranded DNA viruses that 
belong to the family of Papillomaviridae (de Villiers et al., 2004). The circular DNA genome 
of PV has a size of approximately 8 kb containing three major regions: early, late, and an 
upstream regulatory region (URR, also called long control region: LCR). These regions are 
divided by two polyadenylation (pA) sites: early pA (AE) and late pA (AL). The URR covers 
a 850 bp (10% of the HPV genome) long non-coding region, harbouring the origin of 
replication and multiple regulatory transcription factor binding sites for transcriptional 
initiation of the viral early (Bernard et al., 2002) and late promoters (Grassmann et al., 1996). 
About 50% of the viral genome consists of the early region, which encodes six open reading 
frames for the transcription of the early viral proteins E1, E2, E4, E5, E6 and E7. Downstream 
of the early region is the late region, which covers almost 40% of the viral genome and 
encodes the major (L1) and the minor (L2) capsid proteins (Zheng et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 The genome of the human papilloma virus type 16 (HPV-16).  
The different open reading frames for the viral proteins and the upstream regulatory region (URR) are shown. 
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2.2.1 Normal PV infection and productive replication 
 
  The PV replication is tightly controlled and regulated by the keratinocyte 
differentiation (Bedell et al., 1991). The virus usually enters through microlesions of skin and 
mucosa and reaches the basal layers of a stratified squamous epithelium. Infection occurs in 
keratinocytes of the basal layers, which are still able to proliferate. After infection the viral 
genome persists as a stable episome (Stubenrauch and Laimins, 1999; zur Hausen, 2002). 
Upon limited expression of six non-structural viral regulatory proteins (E1, E2, E4, E5, E6 
and E7) from the early region of the viral genome, enhanced proliferation of the infected cells 
followed by their lateral expansion is induced (Stubenrauch and Laimins, 1999; zur Hausen, 
2002; Doorbar, 2006). Hereby E5 plays an important role, as it can form complexes with 
various proliferation stimulating factors like the epidermal growth factor receptor (EGFR), the 
platelet-derived growth factor (PDGF) and the colony stimulating factor-1 receptor (CSFR) 
(Hwang et al., 1995). After reaching the suprabasal layers, the late viral gene expression is 
initiated. Thereby, the proteins E1 and E2 are involved in viral DNA replication and the 
regulation of early transcription. The viral protein E2 plays different roles in viral genome 
replication and maintenance. The most important ones are the recognition and binding to 
DNA within the palindromic motif: AACCg(N4)cGGTT in the URR of the viral genome 
(Dell et al., 2003), and the anchoring of viral episomes to mitotic chromosomes for correct 
segregation (You et al., 2004). E2 binding facilitates the recruitment of E1, a helicase, which 
in turn supports the binding of cellular proteins necessary for DNA replication (Masterson et 
al., 1998; Conger et al., 1999; Loo et al., 2004). This results in amplification of the viral 
genome. In addition, the formation of the structural capsid proteins (L1, L2), which takes 
place exclusively in the nucleus, is induced (Day et al., 1998; Zhao et al., 2000; Buck et al., 
2004). Finally, in the upper layers of the epidermis or mucosa the viral particles are 
assembled and released, whereby the viral protein E4 associates with cytokeratin filament 
collapse in a productive infection (Doorbar et al., 1991; Wang et al., 2004). 
 
2.2.2 High risk PV and the multi-step progression to malignancy  
 
The frequency of infection with a high-risk HPV among young women is usually 20-
40 %, reaching up to 60%, depending on geographical location (Woodman, et al., 2001; 
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Richarsson et al., 2003). Although infections with high risk HPV are very common, only 
women who cannot clear the virus and develop a persistent active infection, lasting years or 
decades, will finally develop cervical cancer (Richardson et al., 2003; Cuschieri et al., 2003; 
Parkin et al., 2002). During this time, progression is accompanied by changes in the 
expression pattern of viral proteins. In CIN1, the viral DNA is still episomal and the typical 
sequential expression of the viral proteins (Figure 2.1), resulting in viral release, is observed 
(Klaes et al., 1999; Fuji et al., 2005; zur Hausen, 2002). A crucial step toward malignancy is  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 The multi-step process leading to cervical cancer.  
The different steps towards malignancy are illustrated with regard to the crucial steps like viral integration, loss 
of both genetic information in form of tumor suppressor genes and control by the immunesystem.  
 
the integration of the viral genome into the genome of the host cells (Jeon et al., 1995; Yu et 
al., 2005). Upon further progression, the productive stages of the virus life cycle are shifted 
towards thinner layers of the epithelial surface until the viral reproduction is no longer 
supported, and the oncoproteins E6 and E7 are expressed throughout the malignant tissue (zur 
Hausen, 2002; Doorbar, 2006). Furthermore, integration of the viral genomes into the host 
genome is preferentially accompanied by the disruption of the region containing the open 
reading frame for the protein E2 (Choo et al., 1987). This leads to the loss of expression of the 
proteins E1, E2 and E5 (Corden et al., 1999). E2 can act as a negative regulator of the E6/ E7 
transcription, by occupying sequences in the HPV promoter region and therefore limiting the 
binding of necessary host transcription factors. (Lewis et al., 1987; Tan et al., 1992; Tan et al., 
infection viral persistence
uncontroled
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1994). Deregulation of viral protein expression and additional pivotal changes in the 
intracellular control mechanisms of the host cells result in an uncontrolled proliferation 
(Woodman et al., 2007).   
A prerequisite for progression to cancer is the escape of the malignant cells from 
detection by the immune system, a phenomenon which is called immune surveillance (Stagg 
et al., 2007). One key event is loss of expression of the chemokine MCP-1, which is induced 
in healthy cells by TNF-α (Figure 2.2) (Rösl et al., 1994). Thereafter, the recruitment of 
effector cells of the immune system to the sites of viral infection ceases, allowing the 
uncontrolled growth of malignant cells (Kleine et al., 1995; Kleine-Lowinsky et al., 1999; 
Kleine-Lowinsky et al. 2003). 
 
2.2.3 The AP-1 transcription factors and their involvement in the 
transcription of HPV  
2.2.3.1 The AP-1 transcription factors  
 
The host cell activator protein 1 (AP-1) complex plays a significant role in the 
transcriptional induction of the HPV URR. The complex is built up by different dimer 
compositions from the members of the JUN, FOS, activating transcription factor (ATF) 
(Bakiri et al., 2002) and musculoaponeurotic fibrosarcoma (MAF) protein families 
(Matsushima-Hibiya et al., 1998; Li et al., 1999). The c-Jun and c-Fos family members 
belong to the immediate early genes (IE) (Herschman et al., 1991). These genes are induced 
within minutes after treatment with the appropriate stimuli, like epidermis growth factor EGF 
(Kajanne et al., 2007), tumor necrosis factor (TNF-α)  (Brenner et al., 1989) and 12-O-
tetradecanoylphorbol-13-acetate (TPA) (Espino et al., 2006). Hence, AP-1 activity is 
controlled by a variety of physiological, pathological and oncogenic stimuli, creating a huge 
diversity of biological functions. Therefore, AP-1 is involved in the induction and regulation 
of cellular responses reaching from proliferation to apoptosis (Angel and Karin, 1991; van 
Dam and Castellazzi, 2001). Whereas Jun proteins are able to homo- (Grondin et al., 2007) 
and heterodimerize (Turner et al., 1989), the Fos family members are only able to 
heterodimerize (Smeal et al., 1989). Depending on the stimulus and the duration of induction, 
different proteins dimerize to build the AP-1 transcription factor (Hess et al., 2004). The 
composition of the dimerisation defines which genes are further induced (Chalmers et al., 
2007). FOS and JUN proteins have been first described as the viral oncoproteins v-Fos and v-
Introduction______________________________________________________________ 
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Jun in the Finkel-Biskis-Jinkins osteosarcoma virus (Curran et al., 1982) and avian sarcoma 
virus 17 (Maki et al., 1987), respectively. AP-1 proteins are characterized by a basic leucin 
zipper domain (bZIP). The leucin zipper is needed for the dimerisation, whereas the basic 
domain allows the interaction with the DNA backbone (Turner et al., 1989; Smeal et al., 
1989). There are different DNA sequences which are recognized by AP-1. The strongest 
sequence is the TPA response element (TRE), but different dimers also bind to the cAMP-
respose element (CRE), the MAF recognition elements (MAREs) and the antioxidant-
response elements (AREs) (Sng et al., 2004; Hess et al., 2004).  
 
2.2.3.2 The AP-1 transcription factors and their involvement in the transcription of HPV  
 
The AP-1 transcription factor is required for the transcription of HPV (Offord and 
Beard, 1990). HPV-16 harbours 3 AP-1 binding sites and HPV-18 2 sites in their URR 
(Figure 2.3). Inactivation by mutagenesis of one site in HPV-18 leads to suppression of the 
HPV transcription (Butz and Hoppe-Seyler, 1993). In addition, similar to the regulation of 
other cellular events, the composition of the AP-1 transcription factor complex is essential for 
the HPV transcription (Soto et al., 1999). Previous experiments with the antioxidant 
pyrrolidine-dithiocarbamate (PDTC) have already shown that induced changing of the AP-1 
composition influences the HPV transcription (Rösl et al., 1997). Besides AP-1 several other 
cellular transcription factors regulate the HPV transcription from the HPV enhancer region 
(Chong et al., 1991, Figure 2.3). 
Taking advantage of a hybrid cellular system, which allows the comparison between 
premalignant and malignant cervical cancer cells, it has been shown that the AP-1 
composition is pivotal for HPV transcription (Soto et al., 1999). HPV-18 positive HeLa cells 
were fused to normal fibroblasts resulting in the cell line 444 which is not tumorigenic in 
immunodeficient nude mice (Soto et al., 1999). In contrast, HeLa cells grow and form tumors 
under the same experimental settings (Soto et al., 1999). Treatment with TNF-α induces 
down-regulation of HPV expression only in 444 cells (Rösl et al., 1994), due to enhanced 
expression of Fra-1 and the accompanied changes in the AP-1 composition from 
predominantly Jun/Jun or Jun/Fos to Jun/Fra-1 dimers. Neither this alteration in the AP-1 
composition, nor the suppression of viral transcription is detectable in HeLa cells or in 
tumorigenic segregants from the 444 cells, namely CGL3, after incubation with TNF-α (Soto 
et al., 1999).    
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Figure 2.3 Schematic overview for the HPV-16 URR.  
Binding sites for transcription factors and repressors in the enhancer, replication origin and promoter region are 
illustrated. The arrow marks the transcriptional start site. Two important nucleosomes which are directly located 
close to the promoter and enhancer regions are also shown. Viral proteins are written in white letters, whereas 
host cellular proteins are black. GR: glucocorticoid receptor, AP1: activator protein 1, NFI: nuclear factor 1, 
TF1: transcription enhancer factor 1, OCT: octamer binding factor 1, TBP: TATA-box binding protein, YY1: 
Yin Yang 1, SF1: steroidogenic factor 1 
 
  
2.2.3.3 MAPK- regulated AP-1 activation 
 
Mitogen activated protein kinases (MAPK) are proline-directed serine/threonine 
kinases, which have been shown to induce AP-1 activation (Whitmarsh and Davis, 1996). The 
MAPK cascades are induced by various extra-cellular stimuli like growth factors, cytokines 
and cellular stress and, in addition to other factors, regulate the AP-1 transcription factor 
complex (Hazzalin and Mahadevan, 2002). After signal transduction MAP-Kinase-Kinase-
Kinases (MAPKKK) are activated by phosphorylation and they in turn activate MAP-Kinase-
Kinases (MAPKK) resulting in phosphorylation of the MAPK (Sng et al., 2004; Young et al., 
2006). Several signal transduction pathways have been related to the final activation of three 
distinct MAPK: extracellular-regulated kinase (ERK) (Chalmers et al., 2007), c-Jun N-
terminal kinase (JNK) and p38 (Hazzalin and Mahadevan, 2002). The activation of MAPK 
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leads to their translocation to the nucleus and subsequent activation of their specific substrates 
(Chen et al., 1992; Brunet et al., 1999; Mizukami, 1997). JNK, for example, phosphorylates c-
Jun on Ser-63 and Ser-73 within its N-terminal activation domain (Hibi et al., 1993). This 
stabilizes and activates c-Jun, which results in the enhanced transcriptional activation of c-Jun 
dependent genes (Musti et al., 1997). Additionally, c-Jun phosphorylation allows the 
recruitment of the coactivator CBP to transcriptional active sequences (Arias et al., 1994). For 
signal termination the kinases are deactivated through dephosphorylation by antagonistic 
phosphatases (Sng et al., 2004). 
 
2.3 The high risk HPV oncoproteins E6 and E7 
 
The transforming potential of the oncoproteins E6 and E7 in vitro has been evidently 
proven by the immortalisation of primary human keratinocytes (Münger et al., 1989; Hawley-
Nelson et al., 1989). The high-risk HPV E6 and E7 oncoproteins are sufficient for induction 
of immortalisation (Münger et al., 1989; Hawley-Nelson et al., 1989).  
Further activation of oncogenes (DiPaolo et al., 1989) or sustained maintenance in 
tissue culture (Dürst et al., 1989) are necessary for the cells to become entirely transformed. 
These experimental approaches again underline the requirement of a multi-step progress to 
carcinogenesis (DiPaolo et al., 1989; Dürst et al., 1989; Snijders et al., 2006). Transgenic 
mouse models expressing the oncoproteins under tissue specific promoters have shown that 
E6 usually induces mostly malignant tumors, whereas E7 was predominantly found in benign 
tumors (Herber et al., 1996; Song et al., 1999). Nevertheless, when expressed together E6 and 
E7 where able to induce malignant tumors (Arbeit et al., 1993; Griep et al., 1993; Comerford 
et al., 1995).  
The HPV E6 protein is about 150 amino acids long and contains two zinc-finger motifs (Cole 
et al., 1987; Barbosa et al., 1989). E6 can induce transformation by targeting p53 to 
proteasomal degradation (Scheffner et al., 1990). During this process E6 first binds to the 
ubiquitin ligase E6AP, particularly to its N-terminal recognition domain (Huibregtse et al., 
1993). This interaction alters the specificity of E6AP toward p53, which leads to p53 
degradation (Huibregtse et al., 1993). Additionally, E6 can directly bind to the p53 C-
terminus (Werness et al., 1990; Li and Coffino, 1996), thereby inhibiting the stabilisation or  
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Figure 2.4. E7 interaction partners and a schematic overview of the E7 structure.  
The already discovered E7 interaction partners are shown in chronological order with the respective interaction 
domain and its function. 
 
 
functional activities of p53 like DNA binding (Lechner et al., 1994; Thomas et al., 1995). p53 
plays a pivotal role as a sensor of cellular stress (Derry et al., 2001) and DNA damage (Gatz 
et al., 2006; Bunz et al., 1998) and is mutated in 40 % of different cancer types (Lengauer, 
1998; Hainaut et al., 1998). Its degradation leads to an increase of mutations and the affected 
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cells lack the ability to undergo apoptosis through the intrinsic pathway. Both effects are 
prerequisites to malignant progression (Fridman and Lowe, 2003; Mihara et al., 2003). An 
additional interaction partner of E6 is the transcriptional activator p300/CBP (Patel et al., 
1999; Zimmermann et al., 1999), which may alter transcription in infected cells. 
The HPV-16E7 protein is 94 amino acids long and can be divided in three functional 
regions: the N-terminal conserved region (CR) 1 and CR2 regions and the C-terminal zinc-
finger domain. CR1 and CR2 have structural and functional homologies to regions of the 
adenovirus E1A and Polyomavirus large T antigen, whereas the zinc-finger domain does not 
show any similarities to E1A or the large T antigen (Phelps et al., 1988; Barbosa et al., 1990). 
E7 has been described to interact with various cellular proteins including retinoblastoma 
protein 1 (pRb) (Dyson et al., 1989; Münger et al, 1989; Figure 2.4). Under normal conditions 
the pRb family members, p110, p107 and p130 interact with E2F thereby inhibiting its 
function (Dyson, 1993). Upon pRb phosporylation in uninfected normal cycling cells, 
conformational changes of pRb leads to the release of transcriptionally active E2F, which in 
turn induces the transcription of proteins for cell cycle progression from G0 to G1 and into the 
S phase (Dyson, 1998). E7 is able to disrupt the pRb-E2F complex by binding to pRb (Dyson 
et al., 1989). The free E2F is now able to induce cell cycle progression. This transition to the 
S-phase is important for ensuring viral DNA replication in normal viral life cycle (Banerjee et 
al., 2006; Flores et al., 2000). In addition, interaction of high risk HPV with pRb induces its 
proteosomal degradation (Münger and Howley, 2002; Gonzalez et al., 2001). Another E7 
interaction has been shown between the S4 ATPase subunit of the 19S regulatory complex of 
the 26 S proteasome and E7 (Berezutskaya and Bagchi, 1997). This is of particular interest as 
it supposes that E7 functions as an adaptor between pRb and the proteasome (Berezutskaya 
and Bagchi, 1997). Until today several E7 interaction partners were discovered and analysed, 
which are summarized in Figure 2.4.  
 
2.4 Epigenetic and cancer     
2.4.1 Epigenetic changes through cancer progression 
 
           The term “epigenetic” defines inherited patterns of altered gene expression which are 
independent of the primary DNA sequence itself. There are three main interrelated 
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mechanisms of epigenetic inheritance: DNA methylation, genomic imprinting and histone 
modifications.  
          In mammals, DNA methylation occurs only at cytosines located 5´ to guanosine (CpGs) 
and is a key element of epigenetic regulation inducing transcriptional silencing (Bird et al., 
2002). CpG islands are accumulated in promoter and enhancer regions of nearly 50% of the 
genes in the mammalian genome (Gardiner-Garden et al., 1987). Furthermore, regarding the 
whole genome, only 20% of the statistically expected CpGs are present (Schorderet and 
Gartler, 1992). This specific CpG distribution underlines the particular importance of gene 
regulation by DNA methylation.  
          Several reports have shown the important role of the DNA methylation status in cancer 
progression (Costello et al., 2000; Esteller et al., 2000; Weber et al., 2005). Particularly, 
cancer cell genomes show simultaneously both global hypomethylation (Gaudet et al., 2003; 
Eden et al., 2003, Rodriguez et al., 2006) and tumor suppressor gene-promoter-specific hyper-
methylation (Jones and Baylin, 2002; Gokul et al., 2007; Nomoto et al., 2007). Feinberg et al. 
provided the first evidence of genome wide DNA hypomethylation in cancer samples 
compared to normal cells (Feinberg et al., 1983). Hypomethylation seems to be linked to 
genomic instability, structural changes in chromosomes and increased gene expression 
(Ehrlich et al., 2002; Rodriguez et al., 2006; Eden et al., 2003). Gene specific activation by 
hypomethylation was defined for the oncogenes R-ras in gastric cancer and for cyclin D2 and 
maspin in pancreatic cancer (Nishigaki et al., 2005; Oshimo et al., 2003; Akiyama et al., 
2003). In HPV induced malignancies, hypomethylation includes HPV genomes resulting in 
carcinogenic progression. For example, in invasive carcinomas only 6 % of HPV-16 DNA is 
methylated whereas 50 % of asymptomatic smears show hypermethylated HPV-16 DNA 
(Badal et al., 2003). These results were further confirmed by De Capoa et al. (2003). 
Furthermore, the oncoproteins E6 and E7 induce numerical and structural chromosome 
instability (Duensing and Münger, 2002), which might be enhanced by hypomethylation of 
the host genomes. Another study demonstrated that the URR and the E6 coding region 
remained unmethylated in almost all analysed samples with patient material from various 
stages of cervical cancer progression (Turan et al., 2006). In addition, direct comparison of 
HPV-18 L1 methylation revealed that L1 was methylated only in caricinomas and can 
therefore be considered as a biomarker for neoplastic progression (Turan et al., 2006). 
In contrast to the genome wide hypomethylation, promoters of important tumor 
suppressors are hypermethylated in many cancer types, whereas in normal cells the same CpG 
islands are not methylated (Jones and Baylin, 2002; Gokul et al., 2006; Nomoto et al., 2007). 
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Of particular interest is that about 50% of the genes which are mutated in the germline, and 
thus cause familiar forms of cancers, are also silenced by methylation in a variety of sporadic 
cancers. Among these genes is the well known breast cancer 1 (BRCA1) (Birgisdottir et al., 
2006), which is mutated in breast cancer. Other affected genes, which are also mutated in 
several cancers, are the retinoblastoma 1 (RB1) (Simpson et al., 2000) and p16 (Blanco et al., 
2007). 
In cervical cancer a growing number of methylated genes have been detected. For example 
suppressor of cytokine signaling (SOCS-1), which is involved in E7 proteasomal degradation 
after IFN-gamma treatment of cervical carcinoma cells, is methylated in 50% of cervical 
carcinomas (Widschwendter et al., 2004). Another interesting link between epigenetic and 
cervical cancer development has been suggested by the recently discovered interaction 
between E7 and the DNA methyltransferase1 (DNMT1). The E7 binding enhances the 
activity of DNMT1 (Burgers et al., 2007). This might be a hint for the involvement of the 
viral protein in methylation of tumor-suppressor genes. Furthermore, E7 might induce the 
transcription of DNMT1 by inducing E2F activity. This has been already shown for other 
viral proteins, like the adenovirus E1A and the polyomavirus BKV large T antigen (TAg) 
(McCabe et al., 2006). E7 is known to induce E2F activity by the degradation of pRb. 
Interestingly, DNMT1 transcription can be induced by E2F1 (McCabe et al., 2005). 
Therefore, E7 might not only induce the transcription of proteins important for cell cycle 
progression through E2F but, as an additional benefit, the transcription of DNMT1 resulting 
in methylation of tumor-suppressor genes. 
Future efforts promise the identification, by microarray based technologies, of novel 
tumor-suppressor genes and their subsequent characterization in the context of tumor 
progression. Epigenetic changes are likely to be an essential first step towards malignancy, 
since additional mutations, needed for further progression, are more easily acquired after 
global hypomethylation and hypermethylation of tumor-suppressor genes. Moreover, analysis 
of the genome methylation patterns will provide biomarkers for defined tumors, for risk 
considerations, early detection of neoplasias and accessibility or response to cancer therapies. 
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2.4.2 Induction of DNA demethylation by DNA-methytransferase inhibitors  
 
Since promoter specific DNA hypermethylation of tumor-suppressor genes has been 
detected in many cancer types, the usage of DNA methyltransferase inhibitors for cancer 
treatment has become a promising new field of investigation (Mund et al., 2006).  
DNA methyltransferases (Dnmts) are a family of enzymes that methylate DNA by adding a 
methyl-group to the carbon-5 position of cytosine residues (Bestor, 2000). In mammals, four 
Dnmt are currently known, namely Dnmt1, Dnmt2, Dnmt3a, Dnmt3b (Bestor et al., 2000; 
Tang et al., 2003). Nevertheless, only three of them are fully active. Dnmt1, which is the 
major Dnmt, has been predominantly shown to maintain the methylation patterns after DNA 
replication and associates with the replication machinery during the S-phase (Leonardt et al., 
1992). Dnmt1 interacts with several proteins involved in epigenetic regulation like HDACs 
(Rountree et al., 2000), HP1, SUV39H1 (Fuks et al., 2003), MeCP2 (Kimura et al., 2002) and 
transcription factors like E2F1, pRb (Robertson et al., 2000) and p53 (Esteve et al., 2005). 
Dnmt3a and Dnmt3b are de novo methyltransferases (Okano et al., 1999).  
The first inhibitors of Dnmt, the nucleotide analogs 5-aza-2’-deoxycytidine and its analog 5-
azycytidine (AC), were synthesized by Sorm and collegues (Sorm et al., 1964). DAC is only 
incorporated into DNA, in contrast to AC which also incorporates into RNA and therefore 
induces cellular activities independent of demethylation. However, DAC is up to 10 times 
more toxic that AC in cultured cells and animals (Bouffard et al., 1994). Despite higher 
toxicity, DAC is usually preferred in both research and clinic, for induction of demethylation, 
due to its ability to strictly bind only to DNA (Jüttermann et al., 1994). Both DAC and AC 
develop their activity following incorporation into the DNA thereby trapping the Dmnt to 
DNA by covalent irreversible binding to the catalytic core, which subsequently decreases the 
amount of free enzyme molecules in the cells resulting in demethylation (Santi et al., 1984). 
DAC is also known as Decitabine. Several reports have proven that Decitabine 
treatment induces demethylation in hypermethylated promoters of tumor-suppressor genes 
leading to their reactivation, and hence phenotypic reversion of cancer cells (Magdinier et al., 
2000; van der Velden et al., 2001).  In clinical studies, Dnmt inhibitors are commonly used 
for treatment of chronic myelogenous leukaemia, sickle cell anemia and myelodyplastic 
syndrome (MDS). Clinical studies for the treatment of other cancer types are proceeding, 
though DAC is not stable in aqueous solution and needs to be administrated frequently 
rendering the treatment inconvenient. Therefore, additional demethylating drugs are currently 
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under study for improving cancer treatment concerning the mode of application and toxicity 
(Lyko and Brown, 2005). 
 
2.4.3 Involvement of DNA methylation in PV gene expression 
 
          The HPV-16 genome contains 112 CpG sites, mainly located on the URR, although 
taking into consideration the genome size (7,900 bp) and the C+G content (40%), about 400 
CpG sites would be expected. This observation is also true for all common HPV types (Myers 
et al., 1994). The enhancer and promoter region of HPV-16 harbours 11 CpG dinucleotides. 
Detailed analysis of the CpG patterns showed that CpG methylation occurs predominantly in 
the URR and in part of the L1 ORF (Rajeevan et al., 2006). The distribution pattern 
underlines that methylation of HPV genomes is important for regulating viral protein 
expression. Indeed, experiments with in vitro methylated HPV-18 URR-directed reporter gene 
expression showed a down-regulation of HPV transcription, which was detected by down-
regulation of CAT activity (Rösl et al., 1993). Additional analysis further verified that CpG 
methylation plays an important role for controlling the transcription of the viral genomes (List 
et al., 1994). Methylation of PV DNA was first detected for the PV1a (Danos et al., 1980, 
Burnett, 1984).  
 
2.4.4 The CaSki cells line as an experimental in vitro model for HPV-16    
genome demethylation 
 
             The HPV-16 positive CaSki cells are of epidermoid origin and were established in 
1977 from a cervical cancer metastasis in the small intestines (Pattillo et al., 1977). CaSki 
cells harbor approximately 600 copies of the viral genome, which are incorporated, mostly in 
tandem, at about 11 sites into the host genome (Mincheva et al., 1987). These incorporated 
HPV genomes are mostly methylated and therefore transcriptionally silent (Rajeevan et al., 
2006). Only one minor HPV DNA-positive locus on chromosome 14 is transcriptionally 
active as nascent HPV RNA was detected by tyramide-FISH (Van Tine et al., 2001). In its 
URR the HPV-16 genome altogether carries 11 CpG sites. Methylation analysis by bisulfite 
treatment revealed, that these CpG sites in CaSki cells are heavily methylated in the promoter 
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and the enhancer region (Kalantari et al., 2004). Later, analysis by pyrosequencing provided 
the tool for detecting the exact methylation status of each CpG site within the URR from each 
individual HPV genome among the total 600 copies in CaSki cells (Rajeevan et al., 2006).  
 
2.4.5  Epigenetic modulation of histones  
 
Besides DNA methylation the recruitment of proteins involved in chromatin 
modification results in the appropriate chromatin configuration for silencing (Burgers et al., 
2003). It is currently known that DNA methylation affects histone modifications and vice 
versa (Johnson et al., 2002; Zhang et al., 2005). However, future experiments will clarify 
whether methylation leads to the initial silencing or if it is a consequence of earlier chromatin 
remodelling events. 
The basic units of chromatin are the nucleosomes. They are built up by an octamer 
consisting of 2 out of 4 highly conserved core histones, namely H3, H4, H2A and H2B. Z 
DNA of 146 bp length is wrapped in 1.6 turns around each nucleosome. The four canonical 
histone proteins contain a central, globular domain, which is connected with the DNA and an 
amino-terminal tail (Kornberg et al., 1974; Finch et al., 1977). The linker histone H1 is 
located between nucleosomes and binds nucleosomes and DNA for further chromatin 
condensation (Thoma et al., 1979). Besides their function as scaffold proteins, histones are 
integrated in a complex network of major cellular regulatory mechanisms for setting of 
epigenetic landmarks. Thereby, the N-terminal tails of the histone proteins, which extend 
beyond the nucleosomal core particles, serve as modules for post-translational covalent 
modifications (Januwein and Allis, 2001; Kouzarides, 2007). These include acetylation of 
lysines, methylation of lysines and arginines, phosphorylation of serine and threonines, 
ubiquitination and sumoylation of lysines and ADP-ribosylation of glutamic acids (Januwein 
and Allis, 2001; Kouzarides, 2007). Since the modified N-termini significantly increase and 
supplement the information potential of the genetic code, this level of epigenetic marking has 
been termed the histone code (Strahl and Allis, 2000). The histone code is enriched by the 
incorporation of core histone variants. In addition, the extension of the modifications plays a 
pivotal role, as lysines can be mono, -di, or trimethylated at the ε-amino group and mono,-or 
di-methylated at arginine residues (Januwein and Allis, 2001). 
For simplification, histone modifications can be divided in two different parts, one 
dealing with transcriptional activation, the other with gene silencing. Acetylation of lysines 
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(Eberharter et al., 2002) and arginine methylation (Bauer et al., 2002) on histones H3 and H4 
residues are accompanied with transcriptional activation. One of the most well studied mark is 
H3 lysine 9 acetylation (H3K9ac). Methylation of lysines plays a dual role. While H3K4me 
(Santos-Rosa et al., 2002), H3K36me (Banister et al., 2005) and H3K79me are marks for 
gene activation, H3K9me (Nakajama et al., 2001) and H3K27me (Cao et al., 2004) are linked 
to gene silencing (Figure 2.5, Figure 2.6). An interesting aspect of histone imprints is that 
they can impinge on each other. For example, in gene activation phosphorylation of H3 at 
serine 10 (H3S10phos) facilitates the acetylation of H3K14 (Lo et al., 2000) and H3K9 (Rea 
et al., 2000) resulting in an open chromatin conformation (Cheung et al., 2000). Additionally, 
acetylation of H3K9 excludes the methylation at H3K9. H3K9me serves as a mark for gene 
silencing (Rea at al, 2000). Therefore it has been postulated that histone modifications act as 
molecular switches, enabling or blocking the setting of other covalent marks (Fischle et al., 
2003). 
A prerequisite for gene silencing and chromatin condensation is the deacetylation of 
histones (Chen et al., 2000; Landry, 2000). Subsequently, the region is marked for gene 
silencing for example by the well studied methylation of H3 at lysine 9 (H3K9me) 
(Nakayama et al., 2001, Rea et al., 2000). Several protein families are involved in setting 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 N-terminal residues of histone H3 and reported modifications.  
The different epigenetic marks are shown. The residues which are known to undergo modifications are 
numbered. Red numbers represent important marks. Arrows represent the outcome of the mark, where (+) means 
activation and (-) repression.  
 
the N-terminal modifications on histones. Intensive research in this field has also shown that 
most of the modifications are dynamic and enzymes and mechanisms which remove the 
histone marks have been described. Only the enzymes responsible for demethylation of 
arginines have not yet been identified. 
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2.4.6 Histone variants 
 
Histones are the basic units of the nucleosomes. The expression of the canonical 
histones, H3, H4, H2A and H2B is tightly regulated and occurs only during the S-phase of the 
cell cycle from the intronless histone genes (Ahmad et al., 2002, Osley, 1991). These 
canonical histones are deposited into the DNA during a process only linked to DNA 
replication (Osley et al., 1991). In addition to the canonical histones other histones, so called 
histone variants or `replacement histones` have been discovered. They are transcribed from 
orphan genes throughout the cell cycle (Sarma and Reinberg, 2005). Therefore they can be 
incorporated into nucleosomes independently from DNA replication. Histone variants are 
known for H1, H3 and H2A. The difference between the canonical histones and their variants 
can range from some amino acids to full additional domains (Sarma and Reinberg, 2005). 
Given their expression throughout the cell cycle the variants are incorporated into chromatin 
at particular sites and they play an important role in epigenetic marking. In the last years 
interesting new insights in the biology and functionality of these histone variants have been 
achieved. Five histone variants for H2A have been described, H2A, H2AX, H2AZ (Redon et 
al., 2002) macroH2A (Chadwick et al., 2001) and H2ABBD (Gautier et al., 2004). Five 
different variants for histone H3 have also been discovered so far, namely H3.1 (the canonical 
histone 3), H3.2, H3.3, CENP-A (Castillo et al., 2007) and H3.1t (Trostle-Weige et al., 1984). 
All of them exhibit different functions. CENP-A is the histone H3 variant which exclusively 
localizes to centromeres. While it has high similarity to the C-terminal part of H3.1, its N-
terminal region strongly differs compared to H3.1. H3.1t is only expressed in testis (Trostle-
Weige et al., 1984).  
Although the histone H3 variants H3.1 and H3.3 differ only in 4 amino acids, their 
incorporation into the chromatin is highly regulated and influences the differentiation between 
transcriptionally active and silenced loci (Ahmand, 2002; McKittrick et al., 2004; Johnson et 
al., 2004; Chow et al. 2005).  
Four residues in the globular domain, which are different between H3.1 and H3.3, are 
responsible for the differential incorporation during the cell cycle and the S-phase restricted 
expression of the H3.1. H3.1 has been described to be incorporated into the nucleosomes in a 
strictly replication dependent (RD) (Tagami et al., 2004) manner, since these four amino acids 
hinder the incorporation outside the S-phase. As H3.3 varies in four amino acids, it can be 
incorporated throughout the whole cell cycle (Tagami et al., 2004). This restriction in the 
H3.1 incorporation profile ensures that, if nucleosomes that are disrupted or lost during 
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transcription, the new nucleosomes will also contain H3.3. Hence, H3.3 is incorporated 
during transcription as a common component of active chromatin and serves in marking 
transcriptionally active regions (Ahmad and Henikoff, 2002). Histone 3 can be modified on 
its N-terminal region at several residues (Figure 2.5). Further experiments have confirmed, 
that H3.3 is enriched for covalent histone modifications associated with active chromatin, 
such as acetylation at Lys9 (K9), Lys18 (K18), Lys23 (K23), di- and tri-methylation at Lys-4 
(K4) (Santos-Rosa, 2002) and methylation at K79 (Strahl and Allis, 2000). In contrast, 
repressive modifications are enriched on the H3.1 histone (McKittrick et al. 2004). H3.1 and 
H3.3 associate with different chromatin-remodelling complexes in vivo. The mechanism of 
H3.3 deposition involves a specialized chaperone complex containing the protein histone cell 
cycle regulation defective homolog A (HIRA). In contrast, the replication-dependent 
incorporation of H3.1 is effected by a replication specific complex that includes chromatin 
assembly factor (CAF-1) (Verreault, 1996; Tagami et al., 2004; Loppin et al., 2005). It has 
been postulated that when H3.3-containing chromatin is more easily transcribed, increased 
transcription may lead to additional replacement of H3.1 by H3.3 (Tagami et al., 2004). 
Therefore, although during replication, the H3.3 nucleosomes will be diluted by newly 
deposited H3.1 nucleosomes, the genomic domains with higher H3.3 content will preserve 
their active status also after the replication, and the H3.1 nucleosomes will once again 
gradually be replaced during ongoing transcription (Nakayama et al., 2007). Regarding this 
model, H3.3 behaves as an epigenetic mark for transcriptionally active chromatin. Several cell 
lines have been tested for their incorporation patterns of H3.3. For a mouse pre-B-cell line it 
has been demonstrated that promoters, but not coding regions, are the principal sites of H3.3 
incorporation (Chow et al., 2005). Additionally, the same distribution was also detected for 
the folate receptor (FR) and Vascular Endothelial Growth Factor-D (VEGF-D) promoter. 
Moreover, the incorporated H3.3 enhanced the expression of FR and VEGF-D (Jin et al., 
2005). However, other genes included in the studies of Jin et al., like beta-globin, did not 
show such promoter restricted incorporation. Another set of experiments showed an 
enrichment of H3.3 in dihydropholate reductase (dhfr) and β-actin promoters after transient 
H3.3 expression throughout the cell cycle (Daury et al., 2006). Taken together, all data 
underline the pivotal role of histone modifications and histone variants in setting and 
maintaining epigenetic inheritance.  
The epigenetic research field has become highly important and for the study of cancer 
development. As epigenetic serves as a mechanism for acquiring new, advantageous inherited 
changes, independently of DNA mutations, which commits normal cells to turn into tumor 
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cells. Progression to cancer has been always described as a multi-step process where different 
abnormal cellular processes finally lead to the uncontrolled proliferation of the cells. 
Therefore, it has been suggested that modifications of the epigenetic state might be the one 
initial step, leading to cellular instability and finally decisive DNA mutations during cancer 
development. Besides this, epigenetic changes are also able to mimic genetic mutations by 
silencing tumor suppressor genes or reactivating oncogenes (Esteller et al., 2000; Ehrlich, 
2002; Ballerstar and Esteller, 2005). 
 
2.4.7  Interaction between different epigenetic mechanisms 
 
Several proteins contain domains for recognition of histone N-terminal modifications. They 
are mainly embedded in multi-protein-complexes, which are responsible for chromatin and 
transcriptional regulation (Rosenfeld et al., 2006). These complexes include transcriptional 
coactivators or corepressors which, upon recruitment by transcription factors, induce the 
adequate chromatin remodelling response. Thereby the recognition specificity, activity and 
histone modifications that are carried out by these complexes are determined by the proteins 
within the complex and their recruitment partners (Rosenfeld et al., 2006). In addition, the 
modulatory roles of covalent modifications on histones or protein-complexes, dictate 
inclusion or exclusion of specific interactive subunits from these complexes (Wang et al., 
2004). Signal-induced interactions of coactivators and corepressors with sequence specific 
transcription factors can be controlled on different levels, including cofactor expression and 
post-translational modifications of both cofactors and their targets (Rosenfeld et al., 2006). 
For example CBP/p300 are known transcriptional coactivators with histone acethylation 
activity and they are part of transcriptional activator complexes. CBP/p300 interact with 
several transcription factors like NFkB (Covic et al. , 1999) and are recruited to promoters 
with specific sequences for these transcription factors, where they are also responsible for 
histone acethylation leading to transcription activation (Strahl and Allis, 2000). On the other 
hand, the well investigated nuclear receptor corepressor (NCoR) complex is involved in 
transcriptional repression (Perissi et al., 2004). Large protein complexes including NCoR and 
HDACs induce transcriptional repression (Wang et al., 2000).  Well studied chromatin 
binding domains are the bromodomain (Haynes et al., 1992), chromodomain (Delmas et al., 
1993), Trp-Asp (WD) WD40 repeats (Couture et al., 2006), Tudor domain (Callebaut and 
Marnon, 1997) and the plant homeo domain (PHD) finger domain (Tripoulas et al., 1996). 
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The bromodomain binds acetylated lysines on histone tails (Owen et al., 2000) and is 
therefore usually connected to transcriptional active regions (Syntichaki et al., 2000). The 
chromodomain recognizes methylated lysines (Jacobs and Khorasanizadeh, 2002), a mark 
which is mainly associated with transcriptional repression, specifically in context of H3K9me 
(Cheutin et al., 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 Interaction between different mechanism and factors involved in establishing and 
maintaining heterochromatin.  
Upon CpG methylation by DNA methyltransferases methylated DNA is in turn recognized by specific binding 
proteins (Nendrich and Bird, 1997), which are able to recruit transcriptional repression complexes. The activity 
of these complexes results in deacetylation of histones (Feng and Zhang, 2001) and setting of the new repressive 
mark H3K9me by histone methyltransferases. This is further recognized by HP-1, which binds to H3K9me 
leading to chromatin condensation (Lachner and Januwein, 2002, Steward et al., 2005). The newly established 
heterochromatin can spread (Ebert et al., 2006) and is replicated late during the S-phase (Wu et al., 2005), where 
predominantly H3.1 is incorporated (Nakayama et al., 2007). This is influenced by the replication machinery, 
which can also interact with other factors. These mechanisms all influence each other (Fuks et al., 2003, Fujita et 
al., 2003) and therefore build up a tightly regulated network, illustrated by the arrows. 
 
The WD40 repeats and PHD fingers also bind to methylated lysines (Ruthenberg et al., 2006, 
Li et al., 2006), whereas Tudor domains are capable of recognizing both methylated lysines 
(Kim et al., 2006, Huang et al., 2006) and arginines (Cote and Richards, 2005). Importantly, 
protein domains that bind to methylated amino acids have been described to differently 
associate with the various states of methylation (mono,-di-tri-methylation) (Forneris et al., 
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2005). Since methylation is known to be involved in both transcriptional repression and 
activation, depending on which amino acid residue is methylated, domains recognizing 
methylation are also involved in both mechanism (Kouzarides, 2007). A brief overview for 
interacting molecules and their function and influences on each other in establishment and 
maintenance of heterochromatin are summarized in Figure 2.6. 
 
2.4.8  The Lysine Methyltransferases and Demethylases 
 
Lysine methyltransferases are enzymes able to specifically recognize and methylate 
lysines on histones and other proteins. They harbor a Suppressor of variegation 3-9 (Su(var)3-
9), Enhancer-of-zeste E(z), Trithorax (Trx) (SET) domain which functions in transferring a 
methyl group from S-adenosyl-L-methionine (AdoMet) to the amino group of a lysine 
residue, leaving a methylated lysine residue and the cofactor by-product S-adenosyl-L-
homocysteine (AdoHcy). The SET domain was first detected as a conserved sequence in three 
Drosophila melanogaster proteins: a modifier of position-effect variegation Su(var)3-9 
(Tschiersch et al., 1994, Rea et al. , 2000), the Polycomb-group chromatin regulator E(z) 
(Jones et al., 1993), and the trithorax-group chromatin regulator trithorax (Trx) (Stassen et al., 
1995). Besides these SET domain protein families, the disruptor of telomeric silencing 
(DOT1) family, which do not possess a SET domain, are also responsible for histone 
methylation, specifically H3K79 (Feng et al., 2002, Ng et al., 2002). 
The histone methyltransferase (HMT) SUV39H1 is one prominent SET domain 
containing protein known to stabilize heterochromatic regions by setting the most general 
histone mark for gene silencing; the H3K9me (Rea et al., 2000). This high affinity binding 
site is specifically recognized by the chromodomain of heterochromatin associated protein 1 
(HP1) (Lachner and Januwein, 2002, Steward et al., 2005). So far, three HP1 proteins have 
been identified in humans HP1α, HP1β and HP1γ. While HP1α and HP1β are predominantly 
associated with pericentric heterochromatin, HP1γ interacts with H3K9me in euchromatin 
(Eisenberg, 2000). Knockout mice for SUV39H1 are prone to develop cancer by impaired 
heterochromatin and genomic stability (Peters et al., 2001). 
The Polycomb group PcG proteins are transcriptional repressors, which can be 
separated into two complexes: the initiation complex, Polycomb repression complex 2 
(PRC2) and the maintenance complex, PRC1. One core protein of the PRC2, namely EZH2 is 
responsible for gene silencing by methylation of the Lys 9 and Lys 27 on H3 (Cao et al., 
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2002; Müller et al., 2002). Notably, EZH2 is overexpressed in many cancers (Varambally et 
al., 2002), correlating with bad prognoses in prostate and breast cancer (Kleer et al., 2003). 
The Trithorax proteins are well described as positive regulators of transcription by 
setting positive methylation marks on histones. One member of the trithorax group has been 
upregulated upon 11q23 translocations in acute leukemias (Tkachuk et al., 1992). Mixed-
lineage leukemia (MLL1) is a H3 Lys 4- specific methyltransferase (Nakamura et al., 2002), 
this mark correlates with transcriptional activity. In addition MLL1 is interacting with the the 
HAT CBP from the SWI/SNF nucleosome remodelling complex (Ernst et al., 2002), thereby 
proceeding transcriptional preinitiation, nucleosome remodelling, histone acetylation and 
histone methylation (Nakamura et al., 2002). 
Lysine demethylation leads to the removal of lysine methylation marks on histones. 
LSD1 demethylates both H3K4 and H3K9 and hence induces transcriptional repression (Shi 
et al., 2004) or activation (Metzger et al., 2005). Other H3K9 demethylases are JHDM2A 
(Yamane et al., 2006), JMJD2B (Fodor et al., 2006), JMJD2C (Cloos et al., 2006) and 
JMJD2D (Shin S, Janknecht R, 2007). 
 
2.4.9 Arginine Methyltransferases and demethylases 
 
Arginine methylation plays a role in transcriptional regulation (Fujiwara et al., 2006), 
translation and DNA repair (Imhof et al., 1999; Bauer at al., 2002). Like lysine methylation, 
arginine methylation promotes either activation or repression. This post-translational 
modification is carried out by the protein arginine methyltransferases family (PRMTs) 
(Kouzarides, 2007). So far, nine members have been discovered. One prominent member is 
the coactivator-associated arginine methyltransferase 1 (CARM-1, PRMT4). Like other 
family members CARM1 is able to methylate histones, but also other proteins. Therefore 
CARM1 has been described as a strong coactivator of transcription and an important protein 
in other cellular processes. For example in the regulation of alternative splicing by 
methylation of splicing factors like Spliceosome-associated protein SAP49, Small 
ribonucleoprotein particle protein B (SmB) and U1C (Cheng et al., 2007). Furthermore the 
RNA-binding proteins HuR (Hongwei, 2002) and HuD belong to the CARM1 substrates 
(Fujiwara et al., 2006). As a transcriptional coactivator CARM-1 is responsible for H3R17 
and H3R26 methylation on the estrogen receptor-regulated pS2 gene and was also described 
to act as a positive regulator of the Cycline E gene (Bauer et al., 2003; El Messaoudi et al., 
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2006). Furthermore, CARM-1 is known to associate with nuclear-receptor associated factors 
and NFkB (Covic et al., 2005). Another important observation is that CARM1 knock-out 
mice die just after birth (Yadav et al., 2003). Arginine methylation is reversed by PAD 
proteins. The direct CARM1 counteracting protein, PAD4 is responsible for the 
demethylation of H3R17 (Wang et al., 2004). 
 
2.4.10 Histone acetylation and deacetylation: the HAT and HDAC 
enzymes 
 
For many genes, a key step in transcriptional regulation is the highly modulated switch from 
gene repression to gene activation. Signal transduction pathways and other communication 
networks in the cell are transmitted to the chromatin remodelling complexes, which in turn, 
depending on several parameters like protein amounts, kinetics, modifications and 
interactions, subsequently activate or repress gene transcription (Rosenfeld et al., 2006). 
During this process, histone acetylation is an essential step in positive transcriptional control 
(Turner et al., 2000). While histone methylation, depending on which amino acid the methyl-
group is added, serves as a mark for both active and silent regions, histone acetylation is 
always associated with actively transcribed genes (Strahl and Allis, 2000). Therefore Histone 
acetyltransferases (HAT) and deacetylases (HDAC) included in holo-complexes play an 
important role in transcriptional regulation. Additionally, besides various histones HATs can 
also modify non histone substrates. HAT complexes have overlapping substrates, but the 
results of acetylation and their regulatory functions varies (Rosenfeld, 2006). For example, 
the HAT complex SAGA preferentially modifies H3K9 but to a less extend also H3K14, 
whereas the NuA3 complex preferentially acetylates H3K14 (Baker et al., 2007, Grant et al., 
1999, Lee and Workman, 2007). Histone acetylation is reversed by HDACs. Deacetylation of 
histone tails by HDACs is inducing transcriptional repression. Chromatin remodelling 
complexes, which also include HDACs are required for switching to the silent chromatin (Lee 
and Workman, 2007). In case of CpG methylation, methyl-CpG-binding –protein 2 (MeCP2) 
specifically binds to the methylated CpG and subsequently recruits the chromatin remodelling 
complex Sin3, which also includes HDAC activity (Jones et al.,. 1998).
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2.5 Aim of this study 
 
Demethylation of intergrated HPV genomes correlates with further progression to 
cervical cancer (Badal et al., 2003). In addition, investigation of oncogene expression levels 
reveals a close relationship between their increase and a poor survival prognosis in cervical 
cancer patients. Interestingly, the viral DNA copy number is not related to the oncogene 
expression level, implying that a number of copies are not transcriptionally active (de Boer et 
al., 2007). Therefore, our understanding of epigenetic mechanisms, which are involved in 
oncogene re-expression, is required for creating new unanticipated approaches for treatment 
of cervical cancer.  
 The aim of my study was to investigate the role of epigenetic mechanisms, namely 
DNA demethylation and histone composition of nuleosomes for re-induction of HPV 
expression. For addressing this question, two different approaches were chosen taking 
advantage of the cervical cancer cell line CaSki, which harbours 600 mostly methylated HPV-
16 copies. 
 
- First, for demethylation of these silenced HPV in CaSki cells were treated with DAC 
and the effects were monitored both on protein and transcriptional level. 
- Second, stable cell clones expressing the histone variant H3.3 were generated in CaSki 
cells and characterized. 
- In addition mass spectrometry analysis was carried out for identifying new potential 
E7 interaction partners. 
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3 Materials and Methods 
3.1 Chemicals 
 
Acrylamid/bis-Acrylamid (29:1), 30% solution   Sigma, Deisenhofen 
Agarose for gel electrophoresis                                             Sigma, Deisenhofen         
Ammoniumpersulfate (APS)      Sigma, Deisenhofen 
Boric acid, p.a.         Sigma, Deisenhofen 
Bovine Serum Albumin         Sigma, Deisenhofen 
Bradford reagent (Biorad Protein Assay)      Biorad, Munich 
Bromphenolblue       Sigma, Deisenhofen 
Chloroform,p.a.      Merck, Darmstadt 
Diethylpyrocarbonate (DEPC)    Sigma, Deisenhofen 
Dimethysulfoxide 100% (DMSO)    Merck, Darmstadt 
di-Sodiumhydrogenphosphate-Dihydrate,p.a.  Roth, Karlsruhe 
DTT (DL-Dithiothreitol)     Sigma, Deisenhofen 
E-64        Roche Diagnostics, Mannheim 
ECL- reagent (Renaissance) NEN Lifescience Products Inc., 
Boston 
EDTA        Roche Diagnostics, Mannheim 
EGTA        Sigma, Deisenhofen 
Acidic acid, p.a 100%     Merck, Darmstadt 
Ethanol, p.a.       Merck, Darmstadt 
Ethidium Bromide solution, 1%     Flunka, Deisenhofen 
Formaldehyde p.a. 37%     Sigma, Deisenhofen 
Foramide, p.a.       Flunka, Deisenhofen 
Gycerine, p.a. 86 %      Roth, Karlruhe 
Glycine       Sigma, Deisenhofen 
Glycogen       Sigma, Deisenhofen 
Urea        Merck, Darmstadt 
HEPES       Gerbu, Gaiberg 
Isoamylalcohol (3-methyl-1-butanol)       Merck, Darmstadt 
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Isopropanol (2-propanol), p.a.    Merck, Darmstadt 
Calciumacetate, pure      Merck, Darmstadt 
Kaliumchloride, p.a.      Merck, Darmstadt 
Kaliumdihydrogenphosphate,p.a.    Roth, Karlsruhe 
Milk powder       Merck, Darmstadt 
Magnesiumchloride-hexahydrate,p.a.   Merck, Darmstadt 
Methanol, p.a.       Merck, Darmstadt 
2- Mercaptoethanol      Sigma, Deisenhofen 
Sodiumacetate, p.a.       Merck, Darmstadt 
Sodiumazid       Sigma, Deisenhofen 
Sodiumchloride,p.a.      Merck, Darmstadt 
Sodiumdodecylsulfate (SDS)     Roche Diagnostics, Mannheim 
3-(N-Morpholino-) propansulfonacid (MOPS)  Gerbu, Gaiberg 
Nodident P40, (NP-40) 10% (w/v)    Roche Diagnostics, Mannheim 
Pefabloc SC       Roche Diagnostics, Mannheim 
Phenol in TE-buffer (pH 7,5)     Roth, Karlsruhe 
Ponceau       Serva, Heidelberg 
Proteinase Inhibitor Mix     Roche Diagnostics, Mannheim 
Hydrochlorideacid, conc.37%, p.a.    Merck, Darmstadt 
TEMED       Sigma, Deisenhofen 
Tris (Tri(hydroxymethyl)aminoethane)   Sigma, Deisenhofen 
Triton X-100 (t-Octylphenoxypolyethoxyethanol)  Sigma, Deisenhofen 
Tween 20       Sigma, Deisenhofen 
 
3.2 Reagents and Media 
 
3.2.1 cell culture: tumour cell lines 
 
5`- Desoxyazacytidine (DAC)    Calbiochem, Bad Soden 
Dimethylsulfoxide (DMSO)     Merck, Darmstadt 
Dulbecco`s modified Eagle`s Medium (DMEM)  Gibco, Eggenstein 
Cyclohexamide (CHX)     Roche Diagnostics, Mannheim 
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Fetal Calf Serum (FCS)     Gibco, Eggenstein 
Geneticin (G-418)      Calbiochem, Bad Soden 
MG-132 (Proteasom–Inhibitor, in solution)   Calbiochem, Bad Soden 
Penicillin 10.000 U/ml     Gibco, Eggenstein 
Phosphate buffered saline (PBS)    Gibco, Eggenstein 
Trypanblue       Sigma, Deisenhofen 
Trypsin/EDTA solution     Gibco, Eggenstein 
Tumor Necrosis Factor- (TNF-α)    Strathmann Biotech, Hannover 
 
Media for freezing: 
10% DMSO 
30% FCS 
60 % DMEM 
 
3.2.2 bacteria culture 
 
Bacto-Agar       Roche Diagnostics, Mannheim 
Bacto-Trypton      Difco, Detroit 
Yeast extract for molecular biology    Difco, Detroit 
Ampicillin, Gibco 
100mg/ml in dH2O, stored at -20°C 
Kanamycin, Gibco 
100mg/ml in dH2O, stored at -20°C 
Luria-Bertani –Media (LB)  
0.1 % (w/v) sodiumchloride 
0.1 % (w/v) Bacto-Trypton 
0.5 % (w/v) Yeast extract     pH 7.2 (NaOH)/ autoclaved 
LB- Plates  
LB-Media, 2% (w/v) Bacto-Agar 
 
3.2.3 Nucleotides, Primers and Oligonucleotides 
[α- 32P] dCTP (10 mCi/ ml)      Amersham-Pharmacia, Braunschweig 
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[γ- 32P]  dATP (10 mCi/ ml)      Amersham-Pharmacia, Braunschweig 
Desoxynucleotides (dATP, dTTP, dCTP, dGTP)   Roche Diagnostics, Mannheim 
 
Gene  Primer- Sequence 5`-3` annealing length 
c-fos 
 
F- AACTTCATTCCCACGGTCAC- 
R - CCTTCTCCTTCAGCAGTTG – 
De-Castro Arce et al., 2004 
55°C 397 bp 
c- jun F-GCATGAGGAACCGCATCGCTGCCTCCAAGT- 
R-GCGACCAAGTCCTTCCCCACTCGTGCACACACT- 
De-Castro Arce et al., 2004 
55°C 409 bp 
fra-1 F-GCGCCTAGGCCTTGTATCTCCCTTTCCCC- 
R-CCGCTCGAGGCGAGGAGGGTTGGAGAGCC- 
De-Castro Arce et al., 2004 
65°C 211 bp 
Jun B F-GCCCTTCTACCACGACGACTC- 
R-CTGCACCTCCACCGCTGCCA- 
De-Castro Arce et al., 2004 
63°C 344 bp 
Jun D F-GGTGCCCGACGTGCCGAGCTT- 
R-GTACGCCGGGACCTGGTGC- 
De-Castro Arce et al., 2004 
61°C 307 bp 
GAPDH F-TGGATATTGTTGCCATCAATGACC- 
R-GATGGCATGGACTGTGGTCATG- 
De-Castro Arce et al., 2007 
65°C 460 bp 
GAPDH 
promotor 
F- CCCAACTTTCCCGCCTCT- 
R- CAGCCGCCTGGTTCAACTG- 
De-Castro Arce et al., 2007 
62°C 293 bp 
HPV-16 
URR1.1 
F-CCGAATTCTGTTGCATGC- 
R-CCTAACAGCGGTATGTAAGG- 
49°c 250 bp 
HPV-16 
URR1.2 
F-CCTTACATCCCGCTGTTAGG- 
R-GCTTGTAAATGTGTAACCC- 
49°C 202 bp 
HPV-16E7 F-CCCAGCTGTAATCATGCATG- 
R-TGCCCATTAAACAGGTCTTCC- 
60°c 269 bp 
H3.3 F-GGGATCCATGGCCCGAACCAAGC- 
R-CTCGAGAGCTCTCTCTCCCCGTATCCG- 
57°C 420 bp 
 
The PCR-primer- sequences, if not otherwise mentioned, have been created using the Primer3 
program from the Whitehead Institutes for Genome Research, Cambridge, MA, USA 
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(http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi). All primers have been 
verified for secondary structures by the program Genewalker and the sequences have been 
blasted by NCBI-blast/human genome for binding similarities. The primer-synthesis has been 
performed either by the nucleotide synthesis facility of the DKFZ or by Invitrogen. 
 
3.2.4 Plasmids  
Name Backbone Insert 
pCMV-Myc-H3.3 pCMV-Myc-tag3B, 
Invitrogen 
cDNA Histone H3.3 
pOZ/h3.3 plasmid pOZ, kindly provided by 
Dr. Nakatani 
cDNA Histone H3.3 
 
3.2.5 Enzymes 
Enzyme company product # concentration recognition site 
DNA     
Taq DNA 
Polymerse 
Invitrogen 10342-020     5     U/µl --- 
T4 DNA ligase NEB M020L  400    U/µl --- 
RNA     
Rnase A Roche 11119915001 500     µg/ml --- 
SuperScript™ II 
reverse-transcriptase 
Invitrogen 18064-022 200     U/µl --- 
Protein     
proteinase K Invitrogen 25530-049   20     U/mg --- 
restriction- enzymes     
BamHI NEB R0136S   20     U/µl 5’...GGATCC...3’ 
3’...CCTAG

G...5’ 
HhaI NEB R0139L   20     U/µl 5’...GCGC...3’ 
3’...C

GCG...5’ 
Xho I NEB R0146S   20     U/µl 5’...CTCGAG...3’ 
3’...GAGCT

C.. 3’ 
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3.2.6 Markers and Kits 
DNA- Standard, Gene Ruler 100 bp DNA-Ladder    MBI-Fermentas, Vilnius 
DNA 6x Loading Dye Solution    MBI-Fermentas, Vilnius 
Protein- Standard Benchmark    Gibco, Eggenstein 
Effectene Transfection Reagent     Qiagen, Hilden 
HexaLabel Plus DNA Labeling Kit    MBI-Fermentas, Vilnius 
Plasmid Purification Maxi-Kit    Qiagen, Hilden 
One Shot TOP 10 E.coli     Invitrogen, Karlsruhe 
QIAquick Gel Extraction Kit     Qiagen, Hilden 
 
3.2.7 Antibodies 
antibody company product #,  
Lot # 
Isotype use  
α-c-Jun Santa Cruz sc-1694, I3004 polyclonal/rabbit 1 : 10000 
α-p-c-Jun Santa Cruz sc-822x, H199 murine IgG 2µg (EMSA) 
1 :10000 (WB) 
α-c-Fos Santa Cruz sc-52x, E268 polyclonal/rabbit 2 µg (EMSA) 
1 : 10000 (WB) 
α-Fra-1 Santa Cruz sc-605x, F229 Polyclonal/rabbit 2 µg (EMSA) 
1 : 10000 (WB) 
α-p53 Santa Cruz sc-126, A1204  murine IgG 2° 1:5000 (WB) 
α-pRb BD-Pharma 554136, 37341 Murine IgG1 1: 500 (WB) 
α-NM2 
    E7 
kindly provided 
by Dr.M.Müller 
 
monoclonal/mouse 1 : 2000 (WB) 
3 µg (IP) 
α-JNK NEB 
cell signaling 
9252, 1  polyclonal/rabbit 1 :1000 (WB) 
α-p-JNK NEB 
cell signaling 
9251S, 3D polyclonal/rabbit 1 :1000 (WB) 
α-p38 NEB 
cell signaling 
9212, 3 polyclonal/rabbit 1 :1000 (WB) 
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α-p-p38 NEB 
cell signaling 
9211S, 6 polyclonal/rabbit 1 :1000 (WB) 
 
α-actin,  ICN 
Biotechnology 
69100, 
7979E 
monoclonal/mouse 1 :100000 (WB) 
α-mouse  
IgG-HRP 
Promega W4021 polyclonal/rabbit 1 : 10000 (WB) 
α-rabbit  
IgG-HRP 
Promega W401B polyclonal/goat 1 : 10000 (WB) 
α- Myc Santa-cruz 9E10 polyclonal/goat 1 : 10000 (WB) 
 
α- Myc abcam 9132-100 
325228 
polyclonal/goat 2 µg ChIP 
 
3.2.8  Cell lines 
cell lines  
HeLa human, cervix/adeno carcinoma, HPV-18 positive, 
50 HPV-18 copies per cell 
Boshart et al., 1984 
SiHa human, cervix/adeno carcinoma, HPV-16 positive, 
1-2 HPV-16 copies per cell 
Baker et al., 1987 
CaSki human, epidemoid carcinoma, HPV-16 positive, 
 ca 600 HPV-16 copies per cell 
Pattillo et al., 1977 
HeLa x SiHa hybrid human, HPV-18 and HPV-16 positive, 
Soto et al., 2000 
HeLa x CaSki hybrid human, HPV-18 and HPV-16 positive, 
Soto et al., 2000 
CaSki x SiHa hybrid human, HPV-16 positive 
kindly provided by Prof. Dr. Rösl 
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3.2.9  Solutions and Buffers 
 
DNA/ RNA   
Poly(dI-dC) 
- 1 mg/ml (10U= 500 µg) in TNE buffer 
- annealing: 5 min at 85°C, cool at RT 
- aliquots stored at -20°C 
 
Biogel-Suspension 
- 1 x TE buffer 
- 5 mM sodium chloride 
- 0.2 (w/v) SDS 
- 50 % (w/v) Biogel 
 
TAE (50 x) 
- 2 M Tris-HCl 
- 0.25 M sodium acetate 
- 0. 05 M EDTA pH 8.0 
- pH 7.8 
 
TBE (10x) 
- 0.9 M Tris base 
- 0.09 M boric acid 
- 0.02 M EDTA pH 8.0 
TBS (1x) 
     -     10 mM Tris-HCl pH 7.5 
     -     100 mM sodium chloride 
TNE (1x) 
- 10 mM Tris-HCl pH 8.0 
- 1  mM EDTA 
- 100 mM sodium chloride 
RNA Loading Buffer(2x) 
- 50% (v/v) Formamide 
- 2.2 M Formaldehyde 
- 1x MOPS-Buffer pH 7.0 
- 1% (w/v) Ficoll (MG 400.000) 
- 0.02 % Bromephenolblue 
- dissolved in DEPC-dH2O 
- aliquots stored at -20°C 
 
DNA lysis buffer (3x) 
- 1.5 % (v/w) SDS 
- 150 mM Tris/HCl pH 8.0 
- 150 mM EDTA 
EMSA binding buffer (5x) 
- 50 % glycerine 
- 60 mM HEPES pH 7.9 
- 20 mM Tris pH 8.0 
- 300 mM potassium chloride 
- 5 mM EDTA 
- 100 µg/ml BSA 
- add protease inhibitors before use 
 
Hybridisation washing buffer 
- 2 x SSC 
- 0.1 % (w/v) SDS 
 
Hybridisation buffer 
      - 50 % Formamide 
      - 10 U/ml tRNA 
      - 5 % SSC 
      - 0.1% Denhardt`s solution 
      - 20 mM sodium phosphate buffer pH 6.5 
      - 1 % (w/v) SDS 
SSC (20x) 
- 3 M sodium chloride 
- 0.3 M tri-sodium citrate de-
hydrate pH 7.0 
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ChIP Lysis buffer 
      -    5 mM Hepes pH8.0 
      -    85 mM KCl 
      -    0.5% NP40 
ChIP buffer 
      -    0.01 % SDS 
      -    1.1% Triton X-100 
      -    1.2 mM EDTA pH 8.0 
      -    16.7 mM Tris pH 8.0 
      -    167 mM NaCl 
ChIP IP buffer 
      -    500 mM NaCl 
      -    50 mM Tris pH 8.0 
      -    5 mM EDTA pH 8.0 
      -    0.5 % NP-40 
ChIP acetylation buffer 
      -    0.1 % SDS 
      -    1% Triton X-100 
      -    20 mM Tris pH 8.0 
      -    150 mM NaCl 
ChIP Lithium Chloride buffer 
      -    250 mM LiCl 
      -    10 mM Tris pH 8.0 
      -    1 mM EDTA 
      -    0.5 % NP-40 
      -    0.5 % sodium, desoxycholate 
TE 
      -    10 mM Tris pH 8.0 
      -    5 mM EDTA 
 
ChIP cocktail buffer 
- 320 mM sodium chloride 
- 80 mM Tris, pH 8.0 
- 20 mM EDTA 
- 100 µg/ ml proteinase K 
 
 
Proteine  
Towbin buffer 
- 25 mM Tris 
- 192 mM glycine 
- 0.1% (w/v) SDS 
- 15 % (v/v) methanol 
Western blot loading buffer 
- 10 % SDS 
- 5 mg bromphenol blue 
- 12.5 % (v/v) 2-β-Mercaptoethan. 
- 5 mM EDTA pH 8.0 
- 50 % glycerine 
- 300 mM Tris pH 6.8 
- store at -20°C 
TBS-T 
- 1x TBS pH 7.6 
- 0.1% (v/v) Tween 20 
PBS 
      -     123 mM sodium chloride 
      -     17.6 mM di-sodium hydrogen- 
             phosphate-dihydrate 
-     10 mM potassium dihydrogen- 
       phosphate 
-      pH 7.5 
Buffer A (also RNA) 
- 10 mM HEPES pH 7.9 
- 10 mM KCl 
- 0.1 mM EDTA pH 8.0 
- 0.1 mM EGTA pH 7.9 
- store at -20 °C 
Buffer C  
      -     20 mM HEPES pH 7.9 
- 25 % glycerine 
- 400 mM sodium chloride 
- 1 mM EDTA pH 8.0 
- 1 mM EGTA pH 7.9 
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RIPA buffer 
-     10 mM Tris pH 8.0 
-     150 mM NaCl 
-     1 mM EDTA 
-     1 % NP40 
-     0.1 % SDS 
-     add PMSF (1 mg/ml) : 100 µl in  
10 ml RIPA buffer before usage 
IP lysis buffer 
-      1 % Triton X-100 
-  50 mM Tris-HCl pH 7.5 
-  500 mM NaCl 
-  5 mM EDTA 
 
silver stain   
fix solution: 
      -     50% EtOH 
- 12% HAc 
- 0.05 % formaldehyde 
staining solution: 
- 200 mg/ 100 ml AgNO3 
- 75 µl/ 100 ml formaldehyde 
developing solution: 
- 60g/l Na2CO3 
- 0.5 ml/l formaldehyde 
- 4 mg/l  Na2S2O3 
stop solution: 
- 50 % methanol 
- 12 % HAc 
Rapid mini-preparation of plasmid DNA   
Reagent I 
     -    10 % glucose (50 mM) 
     -    25 mM Tris-HCl pH 8.0 
     -    10 mM EDTA pH 8.0 
Reagent II 
- 1% SDS 
- 125 mM NaOH 
 
Reagent III 
- 29.5 ml acetic acid (for 100 ml final volume) 
- 3.125 M potassiun acetate 
 
 
 
3.2.10 Materials and Equipment 
 
autoradiography cassettes    Sigma, Deisenhofen 
Centrifuges biofuge pico    Heraeus, Hanau 
         Varifuge RF    Heraeus, Hanau 
         5417R     Eppendorf, Hamburg 
         RC-5 Superspeed with GSA, SS34 Sorvall/ Du Pont, Bad Homburg 
Cell scraper      BD Biosciences, Heidelberg 
Cell culture flasks     Grainer, Nürtigen   
Cryotubes      Grainer, Nürtigen 
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Eppendorf Tubes     Eppendorf, Hamburg 
Filterpaper Whatman 3MM    Schleicher & Schüll, Dassel 
Glass pipettes      Renner, Darmstadt  
Sterile filter      Millipore, Eschborn 
Cell culture flasks     Grainer, Nürtigen   
Bacteria shaker     Infors, Bottmingen 
Beta-Counter QC 2000    Bioscan, Washington D.C. 
Balance AE 160     Mettler, Gießen 
Balance BL 610     Sartorius, Göttingen 
Developing Machine CURIX 60   AGFA Laborgeräte, Gera 
EPS 600      Amersham-Pharmacia, Freiburg 
Geiger Counter LB 1210B    Berthold, Wildbad 
Gel Electrophoresis Chamber   Renner, Dannstadt 
Gel Dryer M.483     Bio-Rad Munich 
Hybridisation oven Hybrid Mini 38   Saur Laborbedarf, Reutlingen 
Incubator B5061 EC/CO2    Heraeus, Hanau 
Microscop CK2     Olympus, Hamburg 
Microwave oven Micromat 241   AEG, Nürnberg 
Neubauer Cell Counting Chamber   Bender & Hobein, Bruchsal 
Nylonmembrane GeneScreen Plus   NEN Lifescience, Boston  
Pipette tips      Steinbrenner Laborsyst., Wiesebach 
PCR-Thermocycler PTC-200   MJ Reserch 
Plastic cuvetts , one way    Grainer, Nürtigen 
pH-Meter Calimetric 765    Knick, Berlin 
Pipettes      Eppendorff, Hamburg 
Pipetboy acu      Integra Biosciences 
Plastic wrap      Toppits, Minden 
Sterile filter      Millipore, Eschborn 
Shaker Rotamax 120     Heildolph, Rust 
Spectrophotometer Ultrospec III   Amersham-Pharmacia, Freiburg 
Sterile Hood BioGard Hood    Baker Company, Sanford 
Sonifier 250      Branson/Heinemann, Schwäbisch Gmünd 
Sonifier Bioruptor     Diagenode, Liège, Belgium 
syringes, one way     BD Bioscience, Heidelberg  
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Thermomixer compact    Eppendorf, Hamburg 
Transilluminator 254 and 366 nm   Vetter, Wiesloch 
Water Bath      Julabo, Seelbach 
Western-Blot Chamber Hoefer, SemiPhor  Amersham-Pharmacia, Freiburg 
Rotomax 120      Heildolph, Rust 
Rockomat      Technomara, Zürich 
Vortex Reax 1DR     Heidolph, Rust 
X-ray films ECL/MP      
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3.3  Cell culture: tumor cell lines  
 
All used human tumor cell lines were adherent growing cells. The stocks from nitrogen 
tank storage were thaw rapidly. Next the cells were dissolved in 25 ml DMEM (Dulbecco`s 
modifies eagle medium) supplemented with 10% FCS (fetal calf serum), 100 µg/ml Penicillin, 
100 µg/ml streptomycin, and centrifuged at 1300 rpm for 4 minutes. Then cells were 
resuspendend in 30 ml medium and plated on cell culture flaks. To avoid cellular overgrow, 
the cultures were splitted twice per week. The cells were washed once with 10 ml PBS and 
incubated in 2 ml Trypsin/EDTA solution until the cells were de-attached from the plates. The 
reaction was stopped adding 10 ml medium. Then cells were diluted 1:10 into new medium. 
 
3.3.1  Cryo-conservation of tumor cells 
 
For conservation 1x 107 cells were trypsinized and centrifuged in media at 1500 rpm for 
4 minutes. The cell pellets were quickly resuspended in 5 ml freezing-media. Then the cell 
suspension was aliquoted into cryo-tubes and cooled down to -80°C. Later the cryo-vials were 
transferred to liquid nitrogen tanks for long term conservation. 
 
3.3.2  Seeding of tumor cells for experiments 
 
The cells were always seeded one day before starting the experiment. For seeding 
cultured cells were trypsinized, dissolved in 10 ml media and counted using a Neubauer-
counting chamber. In order to distinguish between living and dead cells 100 µl cell solution 
was stained with 100 µl trypanblue prior counting. Then the solution was added into the 
Neubauer-counting chamber and cells from each chamber quadrate were counted. The cell 
number was then calculated by the following formula: total counted cells divided by 4 
(number of the quadrates) and multiplicated by 2 (dilution in trypanblue). The acquired 
number X corresponds to Xx104cells/ml. For the DAC experiment that lasted 4 days 
1x106cells were seeded per 60 cm2 plate or 2.5x106cells per 145 cm2 plate.  
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3.3.3 Transfection and establishment of stable cell lines  
All transfection experiments were carried out with Effectene transfection kit using the 
protocol provided by the company for six well plates. The cells were seeded one day before 
transfection and were transfected using 2 µg plasmid DNA per reaction and well.  Three days 
after transfection the cells were trypsinized, seeded on a 60 cm2 plates and incubated in the 
medium containing G418 (Geneticin) for selection. CaSki cells were grown in 700 µg/ml 
G418, whereas the selection medium for SiHa included 1000 µg/ml G418. If necessary the 
dead cells were washed away with PBS and surviving cells were splitted. After 2 weeks 
surviving cells were counted, diluted at a concentration of 10 cells/ml and plated for 
subcloning on 96 well plates containing 100 µl (= 1 cell ) or 200 µl (= 2 cells) per well in 
G418 media. The remaining cells were frozen as transfected stocks. Cell growing was 
monitored over several weeks. At the end each well was checked for cells and wells 
containing only one colony were harvested. Thereby, cells were trypsinized and all cells from 
one well were further grown on 8 cm2 and then 60 cm2 plates. After growing the clones were 
frozen for conservation and 8 clones from each experiment were tested for the Myc-histone-
variant expression from the stable inserted plasmid. 
 
3.4 Protein isolation and analysis of cultured cell lines 
 
Protein was isolated using three different methods depending on the further 
experimental procedure. For EMSA and Western blot proteins were isolated using the 
nucleus-cytosol separation protocol (5.4.1). Proteins were isolated from the nuclear fraction, 
whereas the cytosolic extract was used for RNA isolation. For the detection of MAPK 
activation whole cell lysates were prepared using SDS-lysis buffer (5.4.2). All other Western 
blots proteins were isolated using the RIPA protocol (5.4.3). 
 
3.4.1  Nucleus-cytosol separation 
The advantage of this method is that upon separation of the nuclei from the cytosol 
proteins from each fraction can be analysed independently. For the EMSA experiments the 
nuclear fraction was used. Prior to EMSA, Western blots were performed in order to detect 
any changes in protein content between treated and untreated samples. For the nucleus-cytosol 
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separation cells were harvested from 60 cm2 plates. All following steps were carried out at 
4°C. The cells were washed twice with PBS. Then they were incubated with 1.2 ml of buffer 
A containing 75 µl/ml proteinase inhibitor cocktail (stock: 1 tablet/ml) for 15 minutes. Next, 
the cells were harvested from the plates using a cell scraper and transferred to a 2 ml tube. 
Then 0,625% of the non ionic detergent NP-40 was added and the solution and votexed for 10 
seconds. For further nucleus cytosol separation the solution was centrifuged for 10 seconds at 
13000 rpm. For RNA extraction 1 ml from the supernatant containing cytosolic extract was 
transferred to a 15 ml tube and mixed with 2 ml RLT buffer from QIAGEN RNA extraction 
kit. RLT buffer was prepared prior use by adding 10 µl/ml β-mercaptoethanol. The 
supernatant-RLT-buffer solution was further prepared or frozen at -80°C for conservation. 
The pellet, containing the nuclei, was resuspended in 200 µl of the high-salt buffer C 
following incubation for 15 minutes. Then solution was centrifuged for five minutes at 14000 
rpm. The supernatant with the nuclear proteins was transferred to a new tube and frozen at –
80°C. 
 
3.4.2  Protein extraction using SDS-lysis-buffer 
 
For the analysis of MAPKs activation the proteins were isolated using SDS-lysisbuffer 
(Klotz et al., 1999).  The cells were harvested from 60 cm2 plates after the appropriate 
treatment. For detection of MAPKs activation a positive control was generated by treating the 
cells for 30 minutes with 100U/ml TNF-α. All following steps were carried out at 4°C. Cells 
were washed twice with PBS and subsequently harvested in PBS using a cell scraper. Next, 
cells were centrifuged for 4 minutes at 2000 rpm. The pelleted cells were resuspended in 500 
µl SDS-lysis-buffer. The lysates were sonified 2 times for 10 seconds at 50% power capacity 
and level 3 (Sonifier 250, Branson). Subsequently, the lysates were heated for 5 minutes at 
99°C and centrifuged for 30 seconds at 13000 rpm. An aliquot was used to determine the 
protein concentration by the Bio-Rad DC Protein Assay. The rest was supplemented with 2-
Mercaptoethanol (0.74 M final concentration) and frozen at -80°C. 
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3.4.3  Protein extraction using the RIPA protocol 
 
Cells were harvested from 60 cm2 plates after the appropriate treatment. All following 
steps were carried out at 4°C. Before start 10 µl PMSF/ ml was added freshly to the RIPA 
buffer. The cells were washed twice with PBS. Cells were harvested in PBS using a cell 
scraper and transfer to a 15 ml tube. Then, cells were centrifuged for 5 minutes at 1500 rpm. 
The pellet  was resuspended in 400 µl RIPA buffer/PMSF and sonified 1 time for 10 seconds 
at 50% power capacity and level 3 (Sonifier 250, Branson). The lysate was then incubated on 
ice for 30 minutes and then transferred to a 1.5 ml tube followed by centrifugation for 10 min 
at 4°C and 13000 rpm. Supernatants were collected and frozen at –80°C. 
 
3.4.4  Histone isolation 
 
Preparation of a total histone fraction from nuclei was accomplished by extraction with 
0.2 M H2SO4. This acidic extraction removes histones from DNA. Different H3.3 clones 
were grown up to 95% confluent in 60 cm2 cell culture dishes. Then, cells were washed 2 
times with PBS and trypsinized for 5 minutes at 37°C. Next, cells were collected in 2 ml tubes 
and centrifuged for 5 minutes at 1500 rpm followed by cell lysis in buffer A (5.4.1). For 
nuclei isolation, the samples were centrifuged for 1 minute at 13.000 rpm and the supernatants 
were discarded. Subsequently, the nuclei-containing pellet was incubated with 100 µl 0.2 M 
H2SO4 at 4°C over night. Following this step, the samples were centrifuged for 10 minutes at 
13000 rpm, 4°C and the supernatant was transferred to a new tube. Then, histones were 
precipitated in 900 µl ice-cold acetone at 4°C over night. The samples were centrifuged for 10 
minutes at 13.000 rpm and pellets were dissolved in 60 µl dH2O. For electrophoresis and 
Western blotting 40 µl loading buffer was added to the samples and they were incubated at 
99°C for 5 minutes for denaturation prior separation in a 15% polyacrylamide gel. 
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3.4.5  Detection of protein concentration by Bradford and Lowry 
3.4.5.1 Detection of protein concentration by the Bradford method (Bradford et al., 1976) 
 
The method takes advantage of the dye Coomassie Brilliant Blue 250, which has its 
maximum absorption at 595 nm in complex with proteins. The measurements were carried out 
in a photometer. Since this method is highly influenced by detergents, like SDS, it was used to 
quantify proteins in nuclear extracts and RIPA buffers.  
To generate a standard curve 1-12 µg BSA (Bovine Serum Albumine) were added to a final 
volume of 800 µl dH2O and mixed with 200 µl Bradford Reagent™. To determine the protein 
concentrations 2-3 µl sample were added to 797-798 µl dH2O and mixed with 200 µl 
Bradford Reagent™. Then standards and diluted samples were measured in a photometer at 
595 nm. Using the acquired data from the standards the protein concentrations of the samples 
were calculated. 
 
3.4.5.2 Detection of protein concentration by Lowry 
 
The Bio-Rad DC (detergent compatible) Protein Assay is based on the Lowry protein 
detection principle (Lowry, 1951, Legler et al, 1985), which takes advantage from the 
interaction of the Folin-Ciocalteu-Phenol-Reagent with proteins. The interaction of the 
reagent with tyrosine-residues leads to blue colouring which can be detected at 750 nm. This 
reaction is compatible with higher detergent concentration: maximal 10% SDS and maximal 
2% NP-40. Therefore it was used for detection of proteins in SDS-lysisbuffer. 
Similar to the Bradford method the standards were made using BSA. Thereby standards and 
samples were diluted in 200 µl dH2O and mixed with 100 µl reagent A (1 ml reagent A + 20 
µl reagent C) followed by 800 µl reagent B. The probes were then incubated for 15 minutes at 
RT and analysed in a photophotometer at 750 nm. Again the standards were used as 
references to calculate the protein concentrations of the samples. 
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3.4.6 Western blot Analysis 
3.4.6.1 Protein separation by SDS-PAGE 
 
For analysis the proteins were separated by molecular weight in polyacrylamide 
matrix. In order to migrate, proteins need to be incubated with SDS (sodium dodecyl 
sulphate) and denaturated prior loading to the gel. SDS binds to the amino acids residues in an 
equal amount and charges the proteins negatively. Therefore, they are able to migrate through 
the gel-matrix to the cathode.  Thereby they get separated by their molecular weight, as small 
proteins move faster than the bigger ones. For the experiments the discontinuous SDS-PAGE 
(Laemmli, 1970) was used, where the samples are loaded on a matrix composed of two gels: 
the upper concentrating and the lower separating gel. After entering the lower gel the proteins 
separate according to their molecular weight. For the loading 50-75 µg protein extract from 
RIPA and 30 µg protein from nuclear extracts were adjusted. Proteins were diluted in dH2O 
and SDS-loading buffer (1x final concentration). They were denatured at 99°C for five 
minutes, cooled on ice, centrifuged at 13.000 rpm for 30 seconds and loaded on the gel or 
stored at -20°C for up to one week. After loading, the current was first adjusted at 15 mA/gel, 
allowing migration of the proteins trough the upper gel. Next, for migration trough the 
separating gel the current was increased to 45-60 mA/gel. For the identification of the 
molecular weight, size-standard (Benchmark™) was also loaded on the gel. 
 
3.4.6.2 Western blot 
 
Western blot is the subsequent step after the separation of the proteins in the 
polyacrylaminde gel. The proteins were immobilized on PVDF (Polyvinylidendifluorid) 
membranes using the `semi-dry` method (Towbin et al., 1979, Gallagher et al., 1997). PVDF 
membrane was first activated in 100% methanol for 1 minute, washed in dH2O and incubated 
for at least 15 minutes in Towbin buffer. The blot was built up as follows: Cathode, 9x filter-
paper (Whatman 3MM), PVDF membrane, polyacrylamide gel, 9x filter-paper (Whatman 
3MM) and anode. The blotting was carried in a Western blot chamber (SemiPhor, Amersham-
Pharmacia), where the cathode is located on the bottom plate and the anode is arranged on the 
top of the blot. The protein transfer proceeded at 4°C for 70 minutes with a current of 1.2 mA 
/ cm2 membrane. 
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3.4.6.3 Ponceau- staining and Immunodetection 
 
To monitor protein transfer the membrane was stained with the Ponceau-red-dye and 
then washed with dH2O. This dye binds reversible to proteins. After the staining the 
membrane was incubated for 1 hour at RT in blocking-milk (TBS-Tween, 5% low fat milk) in 
order to block free binding sites on the PVDF membrane. Then the membrane was incubated 
with the appropriate first antibody in blocking-milk over night at 4°C on an over-head turner 
(Rotamax 120). After this period the membrane was washed 3 times for 8 minutes in TBS-
Tween to remove the unbound antibodies. This was followed by incubation of the membrane 
with the specific secondary antibody for 1 hour at RT on an over-head turner (Rotamax 120). 
Subsequently, the membrane was washed and detection of the HRP-labelled secondary 
antibody was carried out using the ECL-System from the NEN Life Science Products Inc. The 
chemiluminescence was detected by autoradiography on films during an exposure time of 20 
seconds to 5 minutes depending on the signal strength.  
 
3.4.6.4 Membrane stripping and storage 
 
 In order to reuse the PVDF membrane for further analysis or for actin control the membrane 
was first washed in TBS, then in water for 5 minutes, followed by incubation for 5 -10 
minutes in 0.2M NaOH. Subsequently, the membrane was washed first in dH2O and then 
TBS for 5 minutes. After these steps the membrane was again blocked and incubated with a 
different antibody. For storage the membrane was left in TBS for up to 2 weeks at 4°C and 
then dried. 
 
3.4.7 Silver stain protocol  
 
Silver staining is a sensitive method for detection of proteins (Blum et al., 1987). The 
polyacrylamide gel, harbouring the separated proteins, was incubated for 20 minutes in fix 
solution and washed in 50 % ethanol 3 times for 10 minutes. Pre-treated in freshly prepared 
0.02% Na2S2O3 solution for 1 minute and rinsed 3 times for 30 seconds. For impregnation the 
gel was incubated for 10 minutes in staining solution and rinsed. Next, the gel was developed 
until first bands were visible and washed 2 times for 2 minutes. For stopping the reaction the 
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stop solution was poured to the gel and incubated for 5 minutes. The gel was washed in H2O 
for one hour at room temperature and dried. 
 
3.4.8 Mass Spectrometry 
 
For mass spectrometry (MS) analysis (Chait et al., 1992; Nelson et al., 1997) E7 co-
immunoprecipitated proteins from DAC and MG132 treated and untreated samples were 
separated on a 12 % polyacrylamide gel. The one-dimensional gel was cut into 14 slices per 
sample. Each individual slice was digested by trypsin and further analyzed by MS. This 
analysis was carried out by the MS core facility of the German Cancer Research Center 
(DKFZ, Funktionelle Proteomanalyse B100). The identified ions were submitted to a data 
base search (Mascot Search) for the corresponding peptides/proteins and the matches were 
qualified by probability Based Mowse Score. Individual ions scores > 37 indicate identity or 
extensive homology (p<0.05). Protein scores are derived from ions scores as a non-
probabilistic basis for ranking protein hits. Only proteins representing a score greater than 37 
were further included as potential E7 interacting partners. For example, peptides detected for 
the protein coactivator-associated arginine methyltransferase 1 (CARM-1), in the DAC 
treated sample, reached a score of 38, as shown in the table below. 
 
gi|40288288  Mass: 66382  Score: 38 Queries matched: 3 
coactivator-associated arginine methyltransferase 1 [Homo sapiens] 
Query  Observed  Mr(expt)  Mr(calc)   Delta Miss Score Expect Rank Peptide 
141  605.71  1209.40  1209.62  -0.22 0  25  0.78 1  R.CLFQSPLFAK.A 
303  700.27  1398.52  1398.75  -0.22 0  33  0.11 1  R.LLTIGDANGEIQR.H 
304  700.72  1399.43  1398.75  0.68 0  (33) 0.15 1  R.LLTIGDANGEIQR.H 
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3.5 Preparation and analysis of nucleic acids  
3.5.1 Detection of nucleic acids concentration 
 
The concentration of nucleic acids was determined by photometry in quartz quvetts. 
Thereby one takes advantage of the optical density of these molecules, which reaches the 
maximum at 260 nm. DNA or RNA was diluted 1:100 in dH2O. The extinction of the diluted 
nucleic acid solution was measured at 260/280 nm. A value of 1.0 corresponds to 50 µg/ml 
DNA, 40 µg/ml ssDNA, 33 µg/ml DNA-oligonuclotides and 40 µg/ml RNA (Sambrook et al., 
1989). To qualify the purity of the analysed samples, the OD260/OD280 quotient was 
calculated. Samples without protein contaminations have a quotient from 1.8 to 2.0.  
 
3.5.2 Separation of nucleic acids by gel electrophoresis 
 
RNA and DNA molecules are negatively charged, due to their phosphate groups, and 
able to migrate within an electric field towards the cathode. This characteristic is used for 
their electrophoretic separation within an agarose gel. Nevertheless, DNA and RNA 
electrophoresis is performed using different protocols. For DNA, the agarose gels are 
prepared by dissolving agarose in 1 x TAE (Tris-Acetat-EDTA) buffer. Depending on the size 
of the DNA fragments, different agarose concentrations are used. DNA molecules between 
0.5- 7 kb are separated in 1.0 % (w/v) agarose gels, whereas molecules of 0.2- 3 kb are 
separated in 1.5 % (w/v) agarose gels. For the detection of both DNA fragments and RNA 
under UV-light (λ = 254 nm), the DNA or RNA intercalating molecule ethidiumbromide is 
added to the agarose solution before polymerisation. As standard, 5 µl of 100 bp DNA ladder 
marker (GeneRuler™ 100 bp ladder) was loaded on the gel. The DNA migration was carried 
out by 7-10 V/cm and the DNA were visualized on a transilluminator. For documentation a 
photo was taken for each DNA or RNA gel.  
To avoid secondary structures of the RNA molecule, its electrophoresis is carried out under 
denaturating conditions, in 1x MOPS buffer and 1.0 % agarose. All material used in RNA 
electrophoresis should be RNase free. 5 µg RNA was added to DEPC-dH2O and RNA 
loading buffer. The solution was incubated at 65°C for 10 minutes to denaturate the RNA. 
After preparation of the agarose-MOPS-buffer-gel the samples were loaded on the gel. For 
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electrophorsis 1x MOPS-DEPC-dH2O buffer was used. The RNA migration was strictly 
carried out at 60V for 2 hours. The risbosomal 18S and 28S RNA was used as a size marker. 
 
3.5.3 Extraction of DNA from tumor cells 
 
For DNA extractions 90-95% confluent cells in 60 cm2 cell culture dishes were washed 
with PBS and lysed in 3 ml DNA-lysis-buffer. The lysate was transferred to a 15 ml tube and 
incubated at 56°C for 1 hour with 100µg/ml proteinase K. Subsequently 3 ml phenol, pH 8.0 
was added to the samples. At this point the samples were either stored for up to 1 week at -
80°C or processed adding 3 ml CIA (Chloroform/Isoamylalcohol, 1:24). The samples were 
transferred to a 15 ml phase lock gel (heavy) tube and mixed for 20 minutes at RT in an over 
head shaker. Next, samples were centrifuged at 4200 rpm at RT for the separation of the 
aqueous phase (containing the DNA) from the organic phase (containing phenol/CIA) and the 
interphase with proteins. Due to the phase lock gel, which is located after this step between 
the interphase and the aqueous phase, the DNA was easily isolated and transferred to a new 
15 ml tube. The DNA was then precipitated by incubation with 0.8 V isopropanol (100%) and 
2 M ammonium acetate, pH 5.2 for 1 hour at -20°C. The DNA was pelleted by centrifugation 
at 4.500 rpm for 1 hour at 16°C. Subsequently, the salt was removed by washing the DNA 
pellet 2 times with 70% ethanol. Last the DNA was air dried, resuspended in dH2O and stored 
at -20°C. 
 
3.5.4 Detection of DNA demethylation by digesting with HhaI 
 
For the DNA demethylation assay one took advantage of the methylation sensitive 
enzyme HhaI (DeCastro-Arce et al., 2007). This enzyme is only able to specifically digest 
DNA within its recognition sequence, when this DNA is unmethylated. Therefore, it was 
possible to analyse if the DNA was demethylated in DAC treated cells. After DNA isolation 
from both DAC treated and control cells, 10 µg DNA was digested with 100U HhaI (NEB) 
and 10% BSA in 1x NEB buffer 4 over night at 37°C in a total reaction volume of 100 µl. In 
order to detect the presence of contaminants that may inhibit the restriction activity 
independent of methylation 5 µl from the 100 µl reaction volume were transferred to a new 
tube which contained 1 µg pBluescript plasmid, dissolved in 5 µl reaction buffer. These 
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control samples were also incubated over night at 37°C and directly analysed on an agarose 
gel. The HhaI activity was determined by the complete digestion of the pBluescript 
plasmid.After the over night digestion, DNA was recovered by phenol/CIA precipitation. 
Thereby the samples were supplemented with 100µl H2O. This solution was transferred into a 
phase lock gel tube (Eppendorf). 200 µl phenol (pH 7.5) and 200 µl CIA were added to the 
samples and mixed for 20 minutes. The samples were centrifuged at 4300 rpm for five 
minutes. The upper phase was transferred to a new tube containing the precipitation mix, 400 
µl ethanol absolute, 20 µl Sodium acetate (3M pH 4.8) and 1 µl glycogen. The solutions were 
gently mixed for 5 minutes and incubated at -80°C for 2 hours. Next, the samples were 
centrifuged at 13.000 rpm for 1 hour. The supernatants were discarded. Pellets were washed 
one time with 70% ethanol, centrifuged at 13000 rpm for 10 minutes and dried at room 
teperature. Then the pellets were resuspended in 50 µl dH2O. To ensure equal DNA amounts 
5 µl of the digested DNA was checked on 1% agarose gel. 
 
3.5.5 Amplification of DNA 
3.5.5.1 Polymerase chain reaction (PCR) 
 
The polymerase chain reaction enables the specific exponential amplification of a 
given DNA sequence (Mullis et al., 1986). The specifity is ensured by the oligonucleotide 
primers. The amplification is carried out by the DNA dependent DNA polymerase Taq from 
Thermus aquaticus, which catalyse the reaction at 72°C. The PCR reaction is divided in three 
different crucial steps, denaturation of the double stranded DNA, annealing of the primers to 
their specific sequence and elongation from the primers to amplify the particular sequence by 
the polymerase Taq. These steps are repeated for several cycles (25-35) to reach the 
exponential amplification of the specific DNA sequence. For the PCR reaction the following 
final concentrations were used: primers: 1.25 mM, MgCl2 0.8 µM, dNTPs :200 µM and 0.625 
U Taq-polymerase in a 25 µl final volume. After the PCR 5 µl of the 6x DNA loading buffer 
was added to the samples and the DNA was visualized on an agarose gel. The ChIP PCR was 
carried out in the Promega master mix following the manufacturer instructions. 
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3.5.5.2 Quantitative PCR 
 
For the quantitative PCR the LightCycler® 1.5 Instrument by Roche was used. During 
the PCR the SYBR green fluorescent dye is incorporated into the newly synthesised DNA. 
After the PCR a melting curve is generated, by slowly heating of the amplicon. This leads to 
denaturation (melting) of the amplified DNA, which changes fluorescence, and is measured 
by the machine. Thereby one takes advantage of the fact, that each double-stranded DNA has 
its own specific melting temperature (Tm), in order to characterize the specifity of the PCR 
amplification/quantification. This is defined as the temperature at which 50% of the DNA 
becomes single stranded. The PCR occurs in specially designed glass capillaries. The 
amplification cycles were as follows: denaturation: 95°C 10 minutes, amplification: 95°C for 
10 seconds, 60°C for 15 seconds, 72°C for 10 seconds. The amplification set up was repeated 
for 50 cycles. The melting curve program was: 95°C, 50°C for 15 seconds and slow heating 
(0.1°C/s) until 95°C for one cycle. As standard a GAPDH-plasmid was used in concentration 
from 15 ng-150 pg.  
 
3.5.6 RNA Isolation from tumour cells 
 
The RNA was extracted from cytosolic fractions during nucleus cytosol separation 
(5.4.1). After centrifugation of the nuclei- buffer A-solution, the supernatant was transferred 
to a 15 ml tube and mixed with 2ml buffer RLT from the Quiagen RNAeasy kit. The 
following steps were carried out following the manufactures recommendations. Briefly, the 
sample was transferred in 700 µl portions to one Qiagen RNAeasy kit spin column and 
centrifuged at 13000 rpm for 30 seconds. The column was washed one time with 700 µl RW1 
buffer and two times with 500 µl RPE buffer. For removal of the ethanol, the column was 
centrifuged at 13000 rpm, for 1 additional minute. Subsequently, the RNA was eluted from 
the column by adding in 30 µl DEPC-H2O (or Qiagen RNase free water). The RNA solution 
was frozen at –80°C. The RNA concentration was determinated either by using a photometer 
or the nano drop technique. Then the RNA was visualized on an agarose gel. 
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3.5.6.1 Reverse transcription of RNA 
 
In order to analyse the expression patterns of a gene on transcriptional level by PCR or 
quantitative PCR the RNA templates need to be reverse transcribed into cDNAs. This reaction 
is carried out by the viral enzyme Reverse Transcriptase, which is a RNA dependent 
polymerase. For initiating the polymerase reaction random primers were used at a 
concentration of 200 ng pro reaction. First the random primers and 1µg RNA were incubated 
in a total volume of 12.5 µl for 10 minutes at 70°C for denaturation of the RNA. After 7 µl 
Master Mix containg 1x RT-buffer, 10 mM DTT, 1 mM dNTP Mix and 1 µl RNase Inhibitor 
was added to the RNA samples and incubated for 10 minutes at 25°C for the primer 
annealing. 100U Reverse Transcriptase Superscript II was added to the samples. Next the 
polymerase reaction was carried out for 50 minutes at 42°C followed by 15 minutes at 70°C. 
For the PCR reactions 1 µl from the 20 µl RT-reaction volume were used. 
 
3.5.6.2 Northern blot  
 
For directly detection of a specific mRNA the isolated RNA was separated on an 
agarose gel and transferred to a Gene Screen + Nylonfilter. The mRNA of interest was 
detected by hydridisation with a radioactive labelled probe. Therefore 50-100 ng of the specic 
probe was labelled using the HexaLabel DNA labelling Kit (MBI Fermentas), following the 
manufacturer instruction. 
 
3.5.6.3 Radioactive labelling for Northern blot 
 
For radioactive labelling, the probe was first denaturated by incubation at 99°C for 5 
minutes. Afterwards the reaction buffer containing 25µCi (α-32P) dCTP, unlabeled 
nucleotides (dATP, dGTP, dTTP), 1U DNA-polymerase (Klenow-fragment) and random 
primers was pipetted to the sample and incubated for 30 minutes at 37°C. To stop the reaction 
1x volume of 2x TNE-buffer was added to the sample. Next, the probe was purified from free 
dNTPs, polymerase and salt by separation over a chromatography column. Prior to 
hybridisation the membrane was incubated in 10 ml hybridisation buffer which contains 
tRNAs, for blocking free unspecific binding sites on the membrane, for 2-4 hours at 42°C. 
The radioactive labelled probe was denaturated at 99°C for 5 minutes and added to the 
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membrane within the hybridisation buffer. After over night incubation the membrane was 
washed with hybridisation washing buffer at 68°C and exposed. Specific hybridisation was 
detected after expose X-ray-films to the membrane for 1-2 days at -70°C. 
 
3.5.7 Analysis of DNA-Protein-Complexes 
3.5.7.1 Electrophoretic Mobility Shift Assay (EMSA) 
 
The electrophoretic mobility shift assay (EMSA) is a protein-DNA-binding assay in 
which the transcription factors bind to their specific DNA recognition sequence (Lewis and 
Conradi, 1996; Soto et al., 1999). EMSA takes advantage of the observation that an unbound 
DNA fragment migrates faster during electrophoresis through a polyacrylamide gel. Proteins 
bound to the fragment significantly slower its migration. This phenomenon is called gel 
retardation. Additionally, using antibodies specific for the transcription factors this method 
allows the identification of the bound proteins. The antibodies bind to the protein-DNA-
complexes generating a much slower migration described as supershift. Radioactive labelling 
of the DNA fragment ensures the visualization of the specific band patterns by 
autoradiography. 
 
3.5.7.2  Annealing and labelling of oligonucleotides 
 
The oligonucleotides were synthesised and delivered as sense and anti-sense ssDNA-
oligonucleotides. In a PCR-Thermocycler 2 µg of each oligonucleotide strand were annealed 
in TNE-buffer for 10 minutes at 85°C followed by cooling down 0.5 °C every 30 seconds. 
This slow temperature decrease enables the complementation of the strands generating 
dsDNA-oligo-nucleotides. 200 ng oligonucleotides were radioactive labelled with 32P-γ-ATP. 
The enzyme T4-Polynucleotide-Kinase transfers the radioactive phosphate to the 
dephosphorylated 5`-end of the oligonucleotides. This reaction was carried out for 30 minutes 
at 37°C and stopped by addition of 4 µl 6x loading buffer. 
In order to purify the labelled oligonuclotides from unincorporated 32P-γ-ATP -molecules the 
reaction was separated on a 15% polyacrylamide gel for 1.5 hours in 1x TBE-buffer at RT and 
200V (ca:35mA). Afterwards the gel was exposed for 30 seconds- 1 minute to an X-ray film. 
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The developed film showed the position of the fragment. The fragment was cut out of the gel, 
sliced in small pieces and incubated at 4°C in 500µl TNE-buffer on a shaker over night.  
 
 Labelling of oligonucleotides for EMSA: 
 
dH2O 2 µl 
200 ng oligonucleotides/ µl stock (annealed) 2 µl 
T4 buffer 10x 1 µl 
32P-γ-ATP 10µCi/µl 4 µl 
T4 Kinase (400U/µl)  1 µl 
Total amount: 10 µl 
 
3.5.7.3 DNA-protein-complexes and gel electrophoresis 
 
Radioactive labelled and purified oligonucleotides were incubated with nuclear extracts. 
During this DNA binding reaction the transcription factors from the nuclear extracts bind 
specifically to the oligonucleotides. In order to diminish unspecific DNA-protein complexes 
the binding buffer contains BSA and Poly(dI-dC). The reaction occurs at RT for 30 minutes. 
Afterwards, for the super shift detection, the antibodies were added to the reaction and 
incubated for 1h at 4°C. Then the samples were loaded on a 5.5% polyacrylamide gel and the 
electrophoresis was performed at 4°C for 30 minutes at 280 V followed by 1 hour and 350 V. 
The gel was dried on 3MM Whatman paper for 1 hour at 80°C and subsequently exposed to 
an x-ray film for detection of different complexes by autoradiography. 
 
3.5.8 Chromatin Immunoprecipiation 
Chromatin immunoprecipitation (ChIP) is a powerful experimental tool to identify proteins 
associated in vivo with specific regions of the genome (DeCastro-Arce et al., 2007). Thereby 
specific antibodies recognizing a specific protein or a specific modification of a protein are 
used. The initial step of ChIP was the cross-linking of protein-protein and protein-DNA in 
live cells with 1% formaldehyde. After 20 minutes incubation at RT the fixation was stopped 
by 0.125M glycine. After cross-linking, the cells were washed one time with 10 ml ice cold 
PBS, following by incubation in trypsin for 20 minutes at 37°C. Then the cells were harvested 
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using a cell scraper and transferred to a 2 ml tube and centrifuged at 1500 rpm for 5 minutes. 
The cell pellet was lysed in 500 µl ChIP lysis buffer containing proteinase inhibitor cocktail 
(Roche). The crude extracts were sonicated to shear the DNA for three times 10 minutes at 
4°C. Next, 25 µl of each sample were de-cross-linked by incubation in 300 mM NaCl over 
night at 65°C. After purification DNA concentration and sonification efficiency was 
determinated. For pre-clearing 25 µg of chromatin were incubated with 40 µg salmon sperm 
DNA and 40 µl Protein A/G-agarose beads (1:1) for two hours at 4°C. Next, the complexes 
were immunoprecipitated over night using 2 µg of the anti-Myc-antibody and the appropriate 
isotype control. Then DNA-protein-antibody complexes were bound to protein-A/G-agarose-
beads during incubation for 2-3 hours at RT. Afterwards, the beads were washed with the 
following buffers: one time with IP buffer, two times with acetylation buffer, two times with 
Lithium-Chloride-buffer and two times with TE buffer. Next, 250 µl of freshly prepared 
elution buffer were added to the beads and samples were rotated for 20 minutes at RT, then 
the samples were centrifuged at 3000 rpm for 5 minutes at RT. 200 µl supernatant was 
transferred to a new tube and mixed with 250 µl freshly prepared cocktail buffer. In addition 
50 µl input (unprocessed chromatin) were mixed with 200 µl elution buffer and 250 µl 
cocktail buffer. In order to digest the proteins the samples were incubated for 2 hours at 37° 
C. Subsequently, the samples were shaked over night at 65°C. DNA was isolated by 
phenol/chloroform extraction and ethanol precipitation. After centrifugation at 13000 rpm for 
30 minutes, 4°C the pellet was dried and resuspended in 60 µl d H2O. The samples were 
either stored at -80°C or analysed by PCR. 
 
3.6 Prokaryotic cells 
 
3.6.1 Bacterial cultures on agar-plates 
 
Bacteria were grown on agar-plates at 37°C. Therefore LB-medium was prepared and 
autoclaved with 15g/l agar. When the solution cooled down at approximately 50°C the 
antibiotics ampicillin or kanamycin were added at a concentration of 100mg/ml. The agar was 
poured over sterile plates and stored at 4°C. For bacterial cells cultivation 100 µl bacteria 
were plated and afterwards grown over night at 37°C. 
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3.6.2 Bacterial growth in solution 
Bacteria were grown in LB medium with either ampicillin or kanamycin over night on a 
shaker at 37°C. Thereby the bacteria were inoculated from the agar-plates-colonies or 
glycerine stocks.  
 
3.6.3 Bacteria conservation and reactivation 
Bacteria stocks were harvested from expontialy growing cells and conserved in 1x volume 
97% glycerine by shock-cooling using liquid nitrogen. Then the stocks were stored at -20°C. 
For reactivation cells from glycerine stocks were picked and inoculated into LB-media for 
subsequent growth at 37°C over night. 
 
3.6.4 Cloning Techniques for generation of the Myc-H3.3-construct 
3.6.4.1 Amplification of the H3.3 cDNA 
 
For cloning the H3.3 cDNA into the pCMV-Myc-tag3B-vector, H3.3 cDNA was 
amplified form the pOZ/h3.3 plasmid (Dr.Nakatani) by PCR using primers containing 
restriction site sequences. The amplification product harbours the following recognitions sites: 
5’ BamHI and 3’ XhoI. Following PCR the BamHI -XhoI fragment was used to further 
engineering the Myc-H3.3 construct. 
 
3.6.4.2 Cloning of the PCR fragment into the pCR®4-TOPO® vector 
 
The restriction digesting is known to function more efficiently, when the enzymes are 
able to bind to an integrated fragment rather than to a PCR product. Therefore the BamHI-
H3.3 cDNA-XhoI fragment was cloned by the TOPO® Cloning Method into the pCR®4-
TOPO® vector following the manufactors instructions (TOPO® cloning reaction). 
Subsequently, One Shot® TOP 10 chemically competent E.coli bacteria were transformed 
with the plasmid and plated on 100 µg/ml ampicilline-LB-agar-plates. In addition, for 
detection of the bacteria harbouring plasmids with the inserted fragment, the bacteria were 
selected by the blue/white-screening method (Ullmann, Perrin, 1970). Therefore 40 µl of 40 
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mg/ml X-Gal in DMF (dimethylformamide) was spread on the top of the agar. After growing 
on these plates the positive (colourless) bacteria were transferred into 5 ml LB-media and 
grown over night. Next, the plasmids were isolated by rapid mini preparations. 
 
3.6.4.3 Rapid mini-preparation of plasmid DNA 
 
For the rapid isolation and subsequent analysis of insertion of the desired fragment 
into the plasmid bacteria cells were transformed and cultured in 5 ml medium over night. 
Next day 1,5 ml were transferred to a new 2 ml tube and  centrifuged for  30 seconds at 
13.000 rpm. Then the pellet was resuspended in 100 µl reagent I. After five minutes 
incubation at room temperature the cells were lysed by adding 200 µl of reagent II. This 
solution was left for five minutes at 4°C. 150 µl reagent III were added to the samples. The 
solution was incubated for five minutes at 4°C and then centrifuged at 13000 rpm for 2 
minutes and 4°C. To precipitate the plasmid DNA the supernatant was transferred to a new 
tube containing 10% final volume sodium acetate (3M), two times sample volume of pure 
ethanol and 1 µl glycogen. The solution was mixed, incubated at 4°C for 20 minutes and 
centrifuged at 14000 rpm for 30 seconds at 4°C. The pellet was washed two times with 1 ml 
70 % EtOH, dried and resupended in 50 µl 0,1x TE. Subsequently, the isolated plasmids were 
digested with BamHI/XhoI. The digestion was visualized on agarose gel followed by recovery 
of the fragment using the QIAquick Gel Extraction Kit. The isolation was carried out 
following the manufactures instructions. 
3.6.4.4 Ligation of the BamHI-H3.3-cDNA-XhoI fragment into the pCMV-Myc-tag3B 
vector. 
 
5 µg of the pCMV-Myc-tag3B vector were digested with 5U of the BamHI/XhoI 
enzymes for 2 hours and analysed on agarose gel. The backbone was isolated using the 
QIAquick Gel Extraction Kit. Afterwards the covalent ligation of the fragment with the sticky 
BamHI/XhoI ends into the BamHI/XhoI-pCMV-Myc-tag3B-backbone was catalysed by 
T4DNA-ligase. This enzyme is able toestablish a phosphodiester bound between a free 5’-
phoshate-group and one 3’ hydroxyl-group. Thereby the fragment was integrated into the 
pCMV-Myc-tag3B backbone. The ligation was carried out incubating 200 ng vector and the 3 
times molar amount of fragment in 20 µl reaction volume at 16°C over night. The reaction 
was inactivated at 65°C for 10 minutes. 10 µl of the ligation was analysed in agarose gel and 
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the other half volume was used for the transformation of One Shot® TOP 10 chemically 
competent E.coli bacteria by heat shock following the manufactures instruction. After 
transformation bacteria were plated on 100 µg/ml Kanamycin-LB-agar-plates over night at 
37°C. Plasmids from 10 different grown colonies were isolated by rapid mini-preparation and 
analysed by enzymatic digestion with BamHI/XhoI. Positive tested plasmids were sent for 
sequencing. Bacteria containing the correct fragment sequence were grown and the plasmids 
were isolated for transfection of CaSki and SiHa cells. 
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4 Results    
4.1 The genome of high risk HPV-16. 
 
HPV-16 has a circular, DNA double stranded genome with a size of 7904 bp, 
containing three major regions: early, late, and the upstream regulatory region (URR, also 
called long control region: LCR). These regions are divided by two polyadenylation (pA) 
sites: early pA (AE) and late pA (AL). The HPV-16 genome encodes eight open reading 
frames, six (E1, E2, E4, E5, E6 and E7) for the translation of the early viral proteins and two 
for the major (L1) and the minor (L2) capsid proteins (Zheng and Baker, 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 The genome of the high-risk HPV-16. 
Schematic representation of the circular DNA genome of HPV-16. The arrows represent the different transcribed 
viral proteins. The URR is highlighted including AP-1 binding sites, potentially methylated CpGs and the HhaI 
restriction site. Other HPV-16 inducing transcription factors are not shown. 
 
 
The URR, covers a 754 bp (10% of the HPV genome) long non-coding region, 
harbouring the origin of replication and multiple regulatory transcription factor binding sites 
for transcriptional initiation of the viral early and late promoters (Chong et al., 1991). The 
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data presented here deal with the analysis of demethylation of HPV-16 genomes and its 
influence on the transcription of the viral oncoprotein E7. Therefore it is important to take 
into consideration that eleven CpG are located within the URR (Rajeevan et al., 2006). Of 
specific interest in this study is the CpG site at nucleotide 7674, which is embedded within a 
HhaI recognition site and was used as an indicator for demethylation. In addition, for the 
transcriptional regulation of the oncogenes, the AP-1 transcription factor complex plays a 
major role (Offord and Beard, 1990; Butz and Hoppe-Seyler, 1993; Soto et al, 1999). There 
are three AP-1 binding sites located in the HPV-16 URR, the one located in the enhancer 
region has been further analysed in this study. Furthermore two particular histones were 
described to occupy defined regions on the enhancer and promoter (Stünkel and Bernard, 
1999). All of these different factors, which together influence each other for initiating or 
silencing the oncogenes transcription, are summarized in the scheme on Figure 4.1. 
 
4.2 Experimental approach to detect DNA demethylation  
 
           DNA methylation, which occurs only at cytosines located 5´ to guanosine (CpGs), 
plays a central role in epigenetical gene regulation by marking genes for transcriptional 
silencing. Besides a pivotal role in development, DNA methylation is also responsible for the 
X-chromosome inactivation in females and the silencing of tumor-suppressor genes in human 
cancers (Jones et al., 2002).  
           In promoter and enhancer regions CpGs are accumulated, whereas in the rest of the 
mammalian genome, only 20% of the statistically expected CpGs are present. This specific 
CpG distribution underlines the particular importance of gene regulation by methylation 
(Schorderet and Gartler, 1992). 
           Both CaSki and SiHa are polyploid HPV-16 positive cells (Patillo et al., 1977; Baker et 
al., 1987; Mincheva et al., 1987). CaSki cells possess approximately 600 mostly methylated 
and therefore transcriptionally silent copies of the HPV-16 genome. They are arranged mainly 
in tandem repeats and are localized over 11 chromosomal sites. In contrast, SiHa cells possess 
2 unmethylated copies of the HPV genomes (Mincheva et al., 1987) To determine whether 
demethylation of the silenced HPV genomes is sufficient for the re-expression of the viral 
oncogenes, CaSki cells were treated with 5-Deoxyazacytidine (DAC). 
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Figure 4.2 Experimental approach and principle for detecting DNA demethylation by digesting 
genomic DNA with the methylation sensitive enzyme HhaI. 
(A) CaSki and SiHa cells were treated for four days with 5-Deoxyazacytidine (DAC). The isolated DNA was 
digested by the methylation sensitive enzyme HhaI. As an internal digest control pBluescript was added. After 
incubation overnight, the pBluescript samples were analyzed on agarose gel. Following isolation of the digested 
genomic DNA, PCR was performed with specific primers for the HPV-16 enhancer region (URR1.1 and 
URR1.2) for detection of demethylation. The demethylated and therefore HhaI digested DNA can not be 
amplified by the URR1.1 primers, that are specific for a region harboring the analysed HhaI restriction site. The 
URR1.2 primers are designed for a region without HhaI recognition sites and are used as DNA quantity control. 
(B) Agarose gel loaded with HhaI digested DNA isolated from cells treated for 4 days with 5 µM DAC and 
untreated controls. 
 
 
In order to detect the demethylation of the HPV-16 genomes after DAC treatment, one 
can take advantage of the methylation sensitive enzyme HhaI, which can distinguish between 
methylated and unmethylated CpGs within its recognition site (5’-GCGC-3’). This property 
enables HhaI to cut DNA only when the embedded CpG is not methylated. Following 
successful DAC treatment, demethylated CpGs are located within HhaI recognition sites and 
the enzyme is able to digest the DNA (Figure 4.2A). Next, for detection of demethylation, the 
digested DNA was analysed by PCR. At sites where the enzyme digested the DNA, no PCR 
products were expected, whereas the uncleaved DNA was amplified. Specific primers for a 
sequence in the URR of the HPV-16 genome, which harbours a HhaI recognition site, were 
designed (URR1.1). Additionally, a primer set for another URR sequence (URR1.2), lacking a 
HhaI recognition site, was used as an experimental control (Figure 4.2A). SiHa cells 
harboring unmethylated HPV (Mincheva et al., 1987) were used as an additional positive 
control. DNA from these HPV genomes is always accessible for HhaI digestion at the 
URR1.1 sequence. From both cell lines, HhaI digested DNA from DAC treated samples and 
controls were visualized in an ethidiumbromide agarose gel (Figure 4.2B).  
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4.2.1 Treatment of CaSki cells with 5-Deoxyazacytidine (DAC) induces 
demethylation of the HPV-16 URR 
 
          The nucleotide analog DAC is incorporated into the DNA and induces demethylation 
by covalent irreversible binding to the catalytic core of DNA methyltransferases (Dmnt). This 
leads to both the functional inhibition and trapping of the Dmnt to DNA (Santi et al., 1984; 
Jüttermann et al., 1994; Schermelleh et al., 2005). DNA demethylation results in opening of 
heterochromatin followed by binding of transcription factors and the transcription initiation 
machinery. This leads to enhanced re-expression of silent genes (Magdinier et al., 2000; van 
der Velden et al., 2001). Previous experiments using DAC have shown that successful 
demethylation of HPV-16 genomes in CaSki cells requires treatment with 5 µM DAC for four 
days. Therefore all experiments have been performed under these conditions. Demethylation 
was detected by DNA digestion with the methylation sensitive enzyme HhaI and subsequent 
PCR (Figure 4.3). Using the HhaI site specific primers (URR1.1) for the HPV-16 URR, no 
PCR product was amplified in SiHa cells. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Treatment of CaSki cells with 5-Deoxyazacytidine (DAC) for four days induces 
demethylation of the HPV-16 enhancer region. 
After treatment of CaSki and SiHa cells for four days with DAC, the isolated DNA was digested with the 
methylation sensitive enzyme HhaI. Subsequent PCR with the URR1.1 and URR1.2 primers was performed.  
 
Untreated CaSki cells could not be cleaved at the same site by HhaI. The data supports 
previous reports that most of the HPV-16 genomes in CaSki cell are methylated (Kalantari et 
al., 2004; Rajeevan et al., 2006). After treatment of CaSki cells with DAC, a significant 
decrease in the specific PCR product using the URR1.1 primers was detected. These results 
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demonstrate that at least half of the 600 HPV-16 genomes in CaSki cells were demethylated 
(Figure 4.3), which was verified in different experiments. In order to ensure equal DNA 
amounts in all samples of the respective cell lines, PCR with the URR1.2 primers was 
performed. Here, no differences were detected (Figure 4.3).   
           Demethylation of the HPV-16 genomes in CaSki cells should result in an enhanced 
expression of the viral oncoproteins, because an increased amount of HPV-16 copies are 
accessible to transcription factors and the initiation complexes.  
 
4.3 Expression analysis of the E7 protein after DAC induced 
demethylation  
4.3.1 Enhanced proteasomal degradation of the oncoprotein E7 after 
DAC treatment in CaSki cells 
 
To determine the level of the oncoprotein E7 expression after DAC treatment in CaSki 
and SiHa cells, Western blot analyses were performed. Since an effective demethylation of 
half of the HPV-16 genomes was detected in CaSki cells, an increase of the E7 expression 
was expected. Surprisingly, no up-regulation of the E7 protein could be detected in these 
cells. In contrast, the expression of the E7 protein was even diminished. SiHa cells did not 
show any down-modulation of E7 (Figure 4.4).  
Previous reports have demonstrated that E7 is targeted for degradation by 
ubiquitination of N-terminal residues and subsequent proteolysis by the 26S proteasome 
(Kamio et al., 2004; Oh et al., 2005). In order to clarify whether E7 degradation after DAC 
treatment in CaSki cells was due to proteasomal degradation the cells were exposed to 20 µM 
of the proteasomal and calpain inhibitor MG132 for 8 hours.  
The analysis of the cell lysates revealed an accumulation of E7 after incubation with 
MG132 in DAC treated CaSki cells, which reached the initial amount of the untreated sample. 
Treatment with the solvent DMSO alone did not rescue E7 from degradation. As controls, 
SiHa cells were treated under the same conditions and showed an E7 accumulation (Figure 
4.4). 
 In order to prove the efficiency of MG132, p53 and pRb, which are known to be 
degraded by the proteasomal pathway, were analysed (Figure 4.4).  In cervical carcinoma 
cells, p53, degradation is mediated by the oncoprotein E6 and its recruitment of the ubiquitin 
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ligase E6AP (Scheffner et al., 1990; Huibregtse et al., 1998). Exposure to MG132 in CaSki 
cells led to an accumulation of p53 in both DAC treated and control samples, which 
demonstrated that MG132 was functionally active.  Interestingly, only SiHa cells do stabilize 
p53 already after DAC treatment alone. In contrast, this accumulation after DAC treatment 
was not detectable in CaSki cells. Nevertheless, an expected additional increase of p53 was 
observed after MG132 treatment in SiHa cells (Figure 4.4). 
pRb is a key regulatory component for cell cycle progression from G1 to S-phase, 
since its degradation induces release of the transcription factor E2F, which leads to 
transcription of proteins required for this cell cycle transition (Weinberg, 1995). E7 binds to 
pRb and this interaction targets pRb to the proteasomal degradation (Münger et al, 1989; 
Gonzales et al., 2001). pRb can be rescued from degradation by MG132 treatment. DAC 
treatment in both CaSki and SiHa cells did not influence the pRb levels. An accumulation of 
pRb was observed after MG132 treatment in CaSki cells. No pronounced accumulation was 
detected in SiHa cells.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Enhanced proteasomal degradation of the oncoprotein E7 after DAC treatment in CaSki 
cells.  
CaSki and SiHa cells were cultivated for 4 days in the presence or absence (control) of 5 µM DAC. After 88 
hours incubation with DAC, the proteasomal and calpain inhibitor MG132 (20 µM) was added for additionally 8 
hours to the DAC medium to ensure the total incubation time of 96 hours with DAC. 60 µg whole cells lysates 
(RIPA) were separated by 8 % / 12% SDS-PAGE and blotted on PVDF membranes followed by incubation with 
antibodies against HPV-16E7, p53, pRb, and actin.  
 
These results imply that the observed E7 degradation after DAC treatment in CaSki 
cells is mediated by the proteasomal and/or calpain pathway. Furthermore, additional 
differences in the proteome activity of CaSki and SiHa cells after DAC treatment were 
detected. Notably, a stabilization of p53 was only observed in SiHa cells.  
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4.3.2 Analysis of the E7 stability after DAC treatment in HeLa (HPV-18) 
and somatic cell hybrid cell lines 
 
Treatment of CaSki cells with DAC induces demethylation of HPV-16 genomes and is 
accompanied by down-regulation of E7 (Figure 4.4). In contrast, DAC treatment does not 
affect the E7 level in SiHa cells. The genetic background of every tumor cell line varies, since 
they were established from different patients and mutations, chromosomal aberrations, 
translocations and epigenetic marks occurred in each cell line. These differences and changes 
influence the composition of the proteome. Hence, the observed enhanced proteasomal E7 
degradation might be, a dominant or recessive peculiarity particular for the genomic  
 
  
 
 
 
 
 
 
Figure 4.5  Schematic representation of the hybrid cell lines.  
Each hybrid cell line was generated by fusion of the parental cell lines CaSki, SiHa (HPV-16) and HeLa (HPV-
18). Therefore these hybrids harbor mixed genomes derived from the parental cell lines and including viral 
genomes from HPV-18 and/or HPV-16 with their epigenetic modifications.  
 
 
background in CaSki cells. In order to address this issue, we took advantage of somatic-cell 
hybrids (Soto et al., 2000). These hybrids harbour the HPV genomes from different parental 
cell lines: in case of HeLa X CaSki cells and HeLa X SiHa cells both HPV-18 and HPV-16 
and in SiHa X CaSki cells only HPV-16 as depicted in Figure 4.5. As demonstrated in Fig. 
3.6., all cell lines showed expression of the oncogene E7 from the incorporated HPV types, 
respectively. In addition, the HPV-18 positive cell line HeLa was also included in this 
approach. 
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4.3.3 Enhanced degradation of the oncoprotein E7 after DAC treatment 
in hybrid cells 
The expression of E7 after DAC treatment in HeLa and hybrid cells was detected by 
Western blot analysis with HPV-16E7 and HPV-18E7 specific antibodies. The experiments 
showed that the amount of the expressed E7 oncoprotein varied among the untreated cell 
lines. HeLa X CaSki hybrid cells expressed the lowest HPV-18E7 amount. HeLa X SiHa 
hybrid cells expressed a higher amount, which was almost equal to HeLa cells (Figure 4.6). 
The HPV-16E7 levels of HeLa X CaSki and SiHa X HeLa hybrid cells were almost equal, but 
clearly less compared to the SiHa X CaSki hybrid cells, which expressed the highest amount. 
Analysis of HPV-16E7 and HPV18E7 levels after DAC treatment unravelled a down-
regulation of both oncoproteins in all analysed cell lines, independently of the viral type. In 
SiHa X CaSki cells the HPV16E7 down-regulation was comparable to the decrease observed 
in CaSki cells. The amount of HPV-16E7 in HeLa X CaSki hybrid cells was also evidently 
reduced and furthermore HPV-18E7 was even not detectable anymore. In HeLa X SiHa  
 
 
 
 
 
 
 
 
 
Figure 4.6 Enhanced degradation of the oncoprotein E7 after DAC treatment in hybrid cells. 
Hybrid cells were cultivated for 4 days in the presence or absence (control) of 5 µM DAC. 60 µg whole cells 
lysates (RIPA) were separated by 12% SDS-PAGE and blotted on PVDF membranes followed by incubation 
with antibodies for HPV-16E7, HPV-18E7 and actin. The figure shows the same membrane for HPV-16E7. Due 
to higher expression of HPV-16E7 in SiHa/CaSki hybrids, the membrane was first exposed for 30 seconds. 
Subsequently, the same membrane was exposed for 90 seconds for detection of the other cell lines. For negative 
controls, either one sample containing HeLa lysate (for HPV-16E7) or SiHa/CaSki lysate (for HPV-18E7) were 
loaded. 
 
hybrid cells, the expression of both proteins, HPV-16E7 and HPV-18E7, was also down-
regulated. Analysis of the HPV-18E7 in HeLa cells showed a decreased level, even more 
pronounced in comparison to HeLa X SiHa hybrid cells. Taken together these experiments 
provide evidence that the DAC induced E7 degradation is not restricted to CaSki cells. It is a 
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common mechanism, independently of the HPV type, at least for the investigated HeLa and 
CaSki cells, and can be extended to hybrid cells containing the genomes of these cell lines. 
 
4.3.4 Identification of E7 interacting proteins 
4.3.4.1 Immunoprecipitation of the oncoprotein E7 
 
Treatment of CaSki cells with the demethylating agent DAC might induce the 
expression of silent genes and therefore up-regulate proteins, which usually are not expressed 
in these cells. This has been shown in other experimental settings and is a general hallmark of 
DAC treatment (Jones at al, 1980). In order to identify novel potential targets of the E7 
oncoprotein, which might induce the observed E7 degradation after DAC treatment in CaSki  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Immunoprecipitation of the oncoprotein E7.   
(A) Silver staining of the E7 IP. CaSki cells were treated with DAC (5 µM, 4 days) and MG132 (20 µM, 8 
hours) and harvested in IP-lysis buffer. After 1 hour lysis at 4°C, the extracts were centrifuged and incubated 
with 30 µl protein A agarose beads and 3 µg of the E7 antibody or 3 µg normal mouse IgG overnight. The 
precipitated proteins were visualized by silver staining of the 12% polyacrylamide gel. (B) Detection of the E7 
oncoprotein by Western blot after IP as described in A.  
 
 
cells, immunoprecipitation (IP) using a HPV-16E7 specific antibody was performed. First, it 
was tested whether the HPV-16E7 antibody was able to recognize the native epitope in an IP 
experiment. CaSki cells were treated with DAC alone or with DAC and the proteasomal 
inhibitor MG132 to stop E7 degradation. Cell lysates, from the different treatments and 
controls, were used for the IP. Subsequent Western blot analysis showed that the native E7 
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was specifically immunoprecipitated by the antibody (Figure 4.7B). As a negative control, 
cell lysates were also incubated with non-specific murine IgGs. In these samples E7 could not 
be detected by Western blot, verifying the specificity of the E7 antibody. The heavy and light 
chain of the IP antibodies were also recognized by the specific secondary antibody, because 
the same murine antibody directed against E7 was used for both IP and the Western blot. 
Importantly, an E7 decrease after DAC treatment (Figure 4.4), was confirmed by IP, as shown 
in Figure 4.7 B, where only a weak E7 signal was detected in the DAC treated sample. 
 In order to identify differences after the IP between the DAC treated and untreated 
samples, the co-precipitated proteins were visualized on a silver stained polyacryamide gel. A 
band can be detected at the expected size for E7 at approximately 14 kDa (Figure 4.7A). 
Additionally, there were slightly visible differences between the band patterns from DAC 
treated versus untreated samples. For example one band was detected at ca 40 kDa, which is 
only visible in the DAC sample, but neither in the control nor in the IgG samples, indicating 
that different proteins may interact with E7 in the presence of DAC. Nevertheless, unspecific 
bands were also detected by using this staining method. These are usually proteins that bind 
unspecifically to the agarose-protein-A-beads.  
 
4.3.4.2 Mass spectrometry analysis of E7 co-precipitated proteins  
 
 
In order to identify novel proteins responsible for targeting E7 to degradation after DAC 
treatment, mass spectrometry (MS) analysis was performed. CaSki cells were exposed to 
DAC and MG132 and harvested in IP lysis buffer. Untreated controls were equally processed. 
Next, the samples were incubated with the antibody against E7. IgG controls were not 
analyzed by mass spectrometry due to the complexity of the method. 
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Figure 4.8 E7 interaction partners identified by MS.   
Immunoprecipitations were carried out with 3 µg E7 antibody in DAC plus MG132 and untreated samples. For 
MS E7 co-immunoprecipitated proteins were separated on a polyacrylamide gel. The one-dimensional gel was 
cut into 14 slices per sample. Each individual slice was digested by trypsin and further analyzed by MS. The 
identified peptides were submitted to a data base search for the corresponding protein. Only proteins 
representing a high detection score were further included as potential E7 interacting partners. Figure 4.8 shows 
an overview of high scored proteins. Additionally, the proteins already known to interact with E7, which were 
also detected here, are summarized (Figure 4.8) and confirm the specifity of our method. The oncoprotein E7 
itself could not be detected, since after the digest by trypsin the remaining peptides are too small for detection by 
MS.  
 
 
4.3.5 The degradation of the oncoprotein E7 is partially mediated by 
calpains 
 
Analysis by mass spectrometry of proteins co-immunoprecipitated with E7 showed the 
presence of the non-ubiquitous calpain 12 only in the DAC treated sample (Figure 4.8). The 
well-conserved family of calcium dependent cystein proteases consists of several ubiquitous 
and cell specific isoforms. Calpains influence a variety of biological processes like migration, 
proliferation and apoptosis (Saez et al., 2006). One domain by which calpains identify their 
potentially targets is the PEST (Pro, Glu, Ser/Thr-rich) domain. E7 possesses a PEST domain 
localized close to the pRb binding site (Antonsson et al., 2006), which might be recognized by 
calpains.  
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Figure 4.9 The degradation of the oncoprotein E7 is partially mediated by calpains. 
CaSki were cultivated for 4 days in the presence or absence  of 5 µM DAC. After 88 hours incubation with DAC 
the proteasomal and calpain inhibitor MG132 (20 µM) was added for an additional 8 hours to the DAC medium 
to ensure the total incubation of 96 hours with DAC. The calpain inhibitor ALLM was added for 4, 6 and 8 hours 
in concentrations of 15 µM and 20 µM. 50 µg whole cell lysates (RIPA) were separated in 12% SDS-PAGE and 
blotted on PVDF membranes followed by incubation with the antibody against HPV-16E7 and actin. 
 
In previous experiments (Figure 4.4), MG132 treatment was shown to rescue E7 from 
DAC induced degradation. MG132 is a strong inhibitor of the proteasome, but also inhibits 
calpains. In order to verify the hypothesis that E7 was degraded by calpains after DAC 
treatment, CaSki cells were incubated for different time periods with different concentrations 
of the pan-calpain inhibitor ALLM (N-acetyl-leucyl-leucyl-methionine) (Stangl et al., 2004). 
As shown in Figure 4.9, this treatment partially rescued E7 from degradation, although it was 
not as efficient as the treatment with MG132 (Figure 4.9). Despite this observation, treatment 
with 20 µM ALLM for more than 4 hours was cytotoxic and induced apoptosis accompanied 
by reduced levels of E7 (Figure 4.9). Therefore, in order to monitor only the calpain 
inhibitory effect, concentration should not exceed 15 µM ALLM in CaSki cells. In summary, 
the exposure of DAC treated cells to 15 µM ALLM for 8 hours led to an accumulation of E7 
which is less pronounced than the accumulation induced by MG132. 
 
4.4 Interaction of CARM1 with the oncoprotein E7 after E7 IP 
 
Mass spectrometry analysis unravelled another interesting protein co-precipitating 
with E7, namely the protein co-activator-associated arginine methyltransferase 1 (CARM1, 
PRMT4) (Figure 4.8). The detected signal was significant and reached a score of 39 with 7 
matched peptides in both DAC treated and untreated samples. CARM1 has been described as 
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a positive regulator of transcriptional promoters by its ability to methylate proteins involved 
in chromatin remodelling, specifically the histone H3 at arginine 17 (Chen et al., 2000) and 
the histone acetyltransferases p300/CBP (Lee et al., 2005). Additional substrates of CARM1 
are the RNA-binding-proteins HuR and HuD (Fujiwara et  al.., 2006).  
 
 
 
 
 
 
 
 
 
Figure 4.10 Interaction of CARM1 with the oncoprotein E7 was detected after E7 IP. 
(A) CaSki cells were harvested in IP-lysis buffer. After 1 hour lysis at 4°C the extracts were centrifugated and 
incubated with 30 µl protein A agarose beads and 4 µg of the E7 antibody or 4 µg normal mouse IgG over night. 
The precipitated CARM1 proteins were detected by Western blot with a CARM1 specific antibody. (B) CaSki 
cells were harvested in RIPA buffer. 50 µg whole cell lysates (RIPA) were separated in the same 8% SDS-
PAGE gel like the IP in A and blotted on a PVDF membrane, followed by incubation with the antibody against 
CARM1. Due to strong IgG and CARM1 signals in the IP, the membrane was first exposed for 20 seconds. 
Subsequently, the same membrane was exposed for 60 seconds for detection of CARM1 in the RIPA extracts. 
 
In order to verify the MS data, IP were performed with the E7 antibody. Subsequently, 
Western blot experiments using an antibody against CARM1 were carried out. After the IP a 
specific band corresponding to the size of endogenous CARM1 was detected (Figure 4.10A). 
This signal was not visible in the IgG control samples. These data were obtained in two 
independent experiments suggesting that CARM1 binds to E7. For monitoring the specifity of 
the CARM1 antibody, RIPA extracts from CaSki cells were loaded with the IP on the same 
gel. Specific bands localized at ca 60 kDa were detected (Figure 4.10B). The different signal 
intensity is due to different exposure times.  
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4.4.1 Down-regulation of CARM-1 in DAC treated CaSki cells 
 
To further investigate the E7-CARM1 interaction, CARM1 levels after DAC treatment 
were analysed by Western blot. Both CaSki and SiHa RIPA extracts were loaded on the gel 
for direct comparison of the two cell lines. CARM1 was expressed in both CaSki and SiHa 
cells to a similar extent. For the previous MS experiment the cells were treated with DAC and 
MG132. This was necessary in order to stop E7 degradation. Therefore, no differences in the 
CARM1 detection levels were observed between the treated and untreated MS samples 
(Figure 4.8). Interestingly, when CaSki cells were treated with DAC alone and analysed by 
Western blot, CARM1, like E7, was also down-regulated. SiHa cells did not show any effect 
(Figure 4.11). This result implies that an important positive regulator of transcription, 
CARM1 deregulated after DAC treatment. 
 
 
 
 
 
 
Figure 4.11  Down-regulation of CARM-1 in DAC treated CaSki cells.  
CaSki and SiHa cells were cultivated for 4 days in the presence or absence (control) of 5 µM DAC. 60 µg whole 
cells lysates (RIPA) were separated by 10% SDS-PAGE and blotted on PVDF membranes followed by 
incubation with antibodies for CARM1. 
 
 
4.5 Analysis of E7 oncogene transcription after DAC induced 
demethylation in CaSki cells 
4.5.1 Treatment with DAC induces a reduction of the HPV-16E7 
transcription 
 
After detection of the E7 degradation on protein level in CaSki cells the transcriptional 
expression levels of the E7 oncogene after DAC treatment were analysed in CaSki and SiHa 
cells. Therefore RT-PCR with HPV-16E7 specific primers was performed. After 
demethylation of the HPV-16 genomes in CaSki cells, an increase of E7 expression was 
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expected. However, this was not the case. In contrast, even a slight, but reproducible down-
regulation of E7 transcription was observed in CaSki cells, whereas in SiHa cells no changes 
in the E7 expression levels were detectable by RT-PCR (Figure 4.12A).  
 
 
 
 
 
 
 
 
 
 
Figure 4.12 Treatment with DAC induces a slightly reduction of the HPV-16E7 transcription.  
(A) RT-PCR. CaSki and SiHa cells were cultivated for 4 days in the presence or absence (control) of 5 µM 
DAC. RT-reaction with 1 µg RNA (in 20 µl volume) and random primers followed by PCR using 1 µl from the 
RT and HPV-16E7 and GAPDH primers. (B) Q-PCR with 1 µl from the RT-sample and HPV-16E7 primers. 
The results were first normalized to the housekeeping gene GAPDH and the adequate control sample.  
 
To further verify these findings, quantitative real time PCR was performed with cDNA 
of DAC treated CaSki and SiHa cells. This approach confirmed the RT-PCR data and an 
approximately 30% reduction in the E7 transcription was determined for the cell line CaSki 
after DAC treatment. In contrast, for SiHa cells 10 % reduction was detected (Figure 4.12B). 
This result indicates that demethylation of the HPV-16 copies in CaSki was not sufficient for 
the transcriptional induction of E7. However, besides DNA demethylation, there are other 
requirements for induction and maintenance of transcription. The most important one is the 
accessibility of transcription factors and the transcription initiation complex to the DNA. 
Demethylation favours the opening of the chromatin but post-translational histone 
modifications and the incorporation of histone variants mark chromatin for activation and 
active transcription (Ahmand K. et al., 2002; McKittrick et al., 2004; Johnson et al., 2004; 
Chow et al. 2005). In addition the composition of transcription factors from the AP-1 family 
is decisive for the initiation of the HPV oncogene expression (Soto et al., 1999). 
Consequently, further experiments were designed to investigate these aspects. 
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4.5.2 Treatment with DAC for four days induces up-regulation of AP-1 
family members in CaSki cells 
 
Previous studies emphasized the essential role of AP-1 composition in transcriptional 
initiation from the HPV enhancer and promoter (Butz and Hoppe-Seyler, 1993; Kyo et 
al.,1997; Rösl et al., 1997). The upstream regulatory region (URR), including the enhancer of 
HPV-16 harbours three AP-1 binding sites (Figure 4.1). It has been demonstrated that a 
successful transcriptional induction is favoured by c-Jun/c-Fos dimers which are known as 
strong activators in contrast to c-Jun/Fra-1 dimers, which act like repressors or attenuators of 
the AP-1 signal (Rösl et al., 1997; Soto et al., 1999). Furthermore, an interaction between E7 
and c-Jun, leading to an enhanced trans-activation by c-Jun, has been described (Antinore et 
al., 1996). CaSki and SiHa cells vary in the copy numbers of their integrated HPV-16 
genomes, namely 600 versus 2-3 copies, respectively (Mincheva et al., 1987). Although most 
of the copies in CaSki cells are transcriptionally silenced by methylation, only one locus of 
the HPV tandem repeats is known to be active (Van Tine et al., 2001). Besides the difference 
in transcriptionally active HPV genomes, another important distinction is their AP-1 
expression pattern. SiHa cells express the AP-1 family members c-Jun, JunD, JunB and c-Fos, 
whereas CaSki cells express c-Jun, Fra-1 and JunB (Soto et al., 2000, Figure 4.13). Therefore 
they exhibit an advantage expressing the strong activators of HPV transcription c-Jun and c-
Fos, whereas CaSki cells are deficient in c-Fos expression. Additionally, due to a deletion, 
SiHa cells lack the binding site for the repressor Yin Yang 1 (YY1), which has been described 
to reduce the AP-1 binding to their recognition sites (O´Connor et al., 1996). These are 
important issues that enable the cells to achieve equal levels of the oncogenes E6 and E7 
expression, besides the extreme difference in HPV copy number. 
The E7 transcription is slightly down-regulated after DAC treatment in CaSki cells, 
despite the expected up-regulation after demethylation of the HPV genomes (Figure 4.12). 
Hence, the composition of the AP-1 transcription factors may play a decisive function for 
transcriptional initiation of HPV. To investigate a potential role of the AP-1 composition, the 
levels of the AP-1 family members, namely c-Jun, c-Fos, Fra-1, JunD and JunB were 
analysed by RT-PCR (Figure 4.13A). 
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Figure 4.13 Treatment with DAC for four days induces up-regulation of AP-1 family members in 
CaSki cells. 
RT-PCR and Western blot analysis of AP-1 family members. (A) CaSki and SiHa cells were cultured for 4 days 
in the presence or absence (control) of 5 µM DAC. RT-reaction was performed with 1 µg RNA (20 µl volume) 
using random primers.  For the following PCR 1 µl from the RT-reaction and primers for the analysed cDNAs 
were used. (B) Western blot analysis of AP-1 family members. CaSki and SiHa cells were cultivated for 4 days 
in the presence or absence (control) of 5 µM DAC. 75 µg whole cells lysates (RIPA) were separated by 10 % 
SDS-PAGE and blotted on PVDF membranes followed by incubation with antibodies against the different AP-1 
family members. 
 
 
After DAC exposure, a strong up-regulation of c-Jun, Fra-1 and JunD was observed in 
CaSki cells, whereas no induction of c-Fos was detectable. In contrast, SiHa cells did not 
show any changes for the examined AP-1 factors (Figure 4.13A). To further validate the RT-
PCR data, Western blot analyses of the AP-1 family members, specifically for c-Jun, Fra-1 
and c-Fos were performed. JunD and JunB were not analysed by Western blot, since no 
qualitatively good antibodies were available. The expression levels of both c-Jun and Fra-1 
were increased in CaSki cells after DAC treatment, whereas no differences were detected in 
SiHa cells (Figure 4.13B). Taking into consideration both the RT-PCR and the Western blot 
data, these results imply that the observed increase of c-Jun and Fra-1 in CaSki cells might 
negatively influence the transcriptional initiation from demethylated HPV genomes. 
Therefore, no up-regulation, but even a slightly down-regulation of the E7 transcription was 
detected after DAC treatment.  
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4.5.3 The up-regulation of AP-1 family members in CaSki cells is 
independent of the activation of the p38 and JNK signalling 
pathways 
 
Mitogen activated protein kinases (MAPK), p38, Jun amino-terminal kinase (JNK) 
and extracellular-signal regulated (ERK) are activated by external signals like growth factors, 
cytokines and stress (Hazzalin and Mahadevan, 2001). MAPK phosphorylate diverse 
transcription factors that initiate the transcription of fos and jun genes, and additionally 
stabilize these proteins by phosphorylation resulting in an enhanced amount of AP-1 
complexes (Hibe et al., 1993; Musti et al., 1997; Hess et al., 2004). Furthermore, the post 
translational phosphorylation, regulated by MAPK, alters the AP-1 activity in its 
transactivating potential and DNA-binding capacity (Morrison, 2003; Hess et al., 2004).  
To exclude that DAC may induce the MAP Kinase pathway, Western blot analyses 
were carried out using phosphorylation specific antibodies for p38 and JNK.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14 Up-regulation of AP-1 family members in CaSki cells is independent of the activation 
of the p38 and JNK signalling pathways.  
CaSki and SiHa cells were treated with 5 µM DAC for 4 days. Western blot with 40 µg whole cell lysate from 
SDS lysis buffer. Incubation of the membrane with antibodies against unphosphorylated and phosphorylated p38 
and JNK. 444 cells were stimulated for 30 min with 100U/ml TNF alpha as positive control for MAPK activities.  
 
In order to prove the specificity of the used antibodies against phosphorylated p38 and 
JNK, 444 cells were included as positive controls. These cells were incubated for 30 minutes 
with 100U TNF to induce MAPK phosphorylation. All cell lines analysed showed almost the 
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same levels of unphosphorylated p38 and JNK. Nevertheless, the phosphorylated forms of 
these MAPKs were only detectable in the TNF alpha treated 444 cells. Neither CaSki nor 
SiHa cells showed enhanced phosphorylation of MAPKs after incubation with DAC (Figure 
4.14). Consequently, the detected up-regulation of the AP-1 family members c-Jun, Fra-1 and 
JunD in CaSki cells after DAC treatment is not induced by MAPKs.  
 
4.5.4 Enhanced binding of c-Jun-Fra-1 dimers to AP-1 consensus and 
AP-1 HPV-16 enhancer sequences after DAC treatment in CaSki 
cells 
 
The previous experiments demonstrated that c-Jun and Fra-1 are up-regulated in CaSki 
cells after DAC treatment. In order to verify that the enhanced c-Jun and Fra-1 expression is 
paralleled by enhanced binding of these transcription factors to their recognition sequences 
electrophoretic mobility shift assays (EMSA) were carried out. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 Enhanced binding of c-Jun-Fra-1 dimers to AP-1 consensus sequence after DAC 
treatment in CaSki cells.  
Dissection of the AP-1 dimerisation patterns by supershift EMSA. CaSki and SiHa cells were cultivated for 4 
days in the presence or absence (control) of 5 µM DAC. 2 µg nuclear extracts were incubated with 32P labeled 
AP-1 consensus oligonucleotides. c-Jun, c-Fos and Fra-1 antibodies were added to the samples and they were 
subsequently separated by electrophoresis.  
 
EMSA is a DNA-binding assay that allows binding analysis of transcription factors 
from nuclear extracts to their specific DNA recognition sequence in vitro (Lewis and Conradi, 
1996). The binding of proteins to a synthetic radioactive labelled DNA-oligonuclotide is 
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detected. EMSA takes advantage of the observation that an unbound DNA fragment migrates 
rapidly during electrophoresis through a polyacrylamide gel, whereas DNA/protein 
complexes significantly slow the migration, causing the phenomenon called gel retardation. 
Additionally by using specific antibodies for the transcription factors of interest, this method 
allows the detection of the complex composition in a qualitative and quantitative manner. 
  
For EMSA experiments, different oligonucleotides were used: the AP-1 consensus 
sequence, the AP-1 HPV-16 enhancer sequence and the Oct-1 sequence as binding control. 
(see Figure 4.15 lane 1-8/ Figure 4.16 lane 1-8, Oct-1). An increased binding of the proteins 
c-Jun and Fra-1, which had elevated levels, were detected in nuclear extracts from the DAC 
treated CaSki cells using AP-1 consensus and AP-1 HPV-16 enhancer sequences. Moreover, 
for these oligonucleotides, no binding of c-Fos was observed in CaSki cells, neither in the  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16 Enhanced binding of c-Jun-Fra-1-dimers to the AP-1 HPV-16 enhancer sequence after 
DAC treatment in CaSki cells.  
Dissection of the AP-1 dimerisation patterns by supershift EMSA.  CaSki and SiHa cells were cultivated for 4 
days in the presence or absence (control) of 5 µM DAC. 2 µg nuclear extracts were incubated with 32P labeled 
AP-1 HPV-16 enhancer oligonucleotides. c-Jun, c-Fos and Fra-1 antibodies were added to the samples and they 
were subsequently separated by electrophoresis.  
 
 
control samples nor after DAC treatment. SiHa cells showed only a faintly increased binding 
of c-Fos after DAC treatment for both AP-1 consensus and AP-1 HPV-1 enhancer sequences. 
In comparison to a significant increase in CaSki cells (comparing lane 2 to lane 6 for c-Jun 
and lane 4 to lane 8 for Fra-1). The c-Fos increase in SiHa cells (compare lane 3 to lane 7) is 
not significant (Figure 4.15/Figure 4.16). Additionally, no increase in the c-Jun binding for 
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the investigated sequences was detectable, as shown by the comparison between the bands in 
lane 2 to lane 6. Furthermore, Fra-1 was not detectable as AP-1 component in SiHa cells, 
which again confirms the Western blot data. These results reveal a strong increase of c-Jun 
and Fra-1 binding upon DAC treatment in CaSki cells, however the treatment did not induce 
any changes of the AP-1 composition (Figure 4.15/Figure 4.16).  
 
4.5.5 Treatment with DAC does not affect the HPV-16E7 transcription, 
while it induces changes in HPV-18 transcription. 
 
For the analysis of the E7 protein levels after DAC treatment, somatic cells hybrids 
between SiHa, CaSki and HeLa were investigated. The advantage of such cell hybrids is that 
they allow a direct comparison to the parental cell lines and the involvement of trans- 
dominant or trans-recessive cell specific factors. To analyse E7 transcription after DAC 
treatment of the hybrids, RNA was isolated and analysed by RT-PCR for HPV-16E7 or 
Northern blot for HPV-18. On protein level, hybrids and HeLa cells exhibit a degradation of 
E7 after incubation with DAC (Figure 4.6). However, on transcriptional level, the cells differ 
from CaSki cells. A significant change of E7 transcription was not detectable, neither for the 
hybrids nor for HeLa cells. An exception is the hybrid cell line HeLa/SiHa, which did not 
show any changes in HPV-16E7, but a drastically decrease of HPV-18 mRNA expression 
after DAC treatment. HPV-16E7 primers do not recognize the HPV-18 cDNA, therefore no 
amplification was detected in HeLa cells. All analysed hybrids do express HPV-16E7, 
interestingly in comparable amounts (Figure 4.17). In contrast to HPV-16E7, HPV-18 mRNA 
is expressed differently among the hybrids. Under control conditions, HPV-18mRNA 
expression is very low in HeLa/CaSki hybrids, which corresponds to the Western blot results, 
where the HPV-18E7 protein expression was also the lowest (Figure 4.6). While HeLa cells 
and HeLa/SiHa hybrids show almost the same high amounts. After DAC treatment a slight 
down-regulation of HPV-18 mRNA was detected in HeLa cells and a strong in HeLa/SiHa 
cells. In contrast DAC treatment did not change the expression levels in HeLa/CaSki hybrids 
(Figure 4.17).  
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Figure 4.17 Treatment with DAC does not affect the HPV-16E7 transcription in all analysed cell 
lines, while it induces changes in HPV-18 transcription.  
Cell lines were cultivated for 4 days in the presence or absence (control) of 5 µM DAC. (A) RT-reaction with 1 
µg RNA (in 20 µl reaction volume) and random primers followed by PCR using 1 µl from the RT-reaction and 
HPV-16E7 and GAPDH primers. (B) Northern Blot with 5µg RNA, hybridized with 32P radioactive labelled 
HPV-18 specific probe.  
 
 
4.6 Generation of stable clones expressing the histone 3 variants 
H3.1 and H3.3 in the cell lines CaSki and SiHa 
 
New exciting insights into the biology of histones have been established in recent years. 
First, the histone code theory, which underlines an important role of post-translational 
modifications of histones for the organization of chromatin conformation and therefore 
transcriptional regulation, was established (Allis et al, 2000). Now another crucial mechanism 
for marking transcriptional states has been discovered, namely the insertion of histone 
variants (Ahmand et al., 2002). Five different variants have been discovered so far for histone 
H3, H3.1, H3.2, H3.3, CENP-A and H3.1t (Allis et al, 2000). Although the histone H3 
variants H3.1 and H3.3 differ only in 4 amino acids (Figure 4.18A), their incorporation into 
the chromatin is highly regulated and influences the differences between transcriptionally 
active and silenced sites (Ahmand et al., 2002; McKittrick et al., 2004; Johnson et al., 2004; 
Chow et al. 2005). In previous experiments, no up-regulation of E7 could be detected in 
CaSki cells after DNA demethylation. Therefore, demethylation of silenced HPV genomes 
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alone is not sufficient for induction of viral transcription. Thus, it was supposed that the 
incorporation of a stably expressed H3.3 variant, which marks transcriptionally active 
sequences, may alter the chromatin composition of the DAC demethylated HPV genomes 
towards a favorable state for transcription.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18 Generation of stable clones expressing the histone 3 variants H3.1 and H3.3 in the cell 
lines CaSki and SiHa.  
(A) Schematic overview of the nucleosome core, the different H3 variants and the structure of the Myc-tagged 
histone 3.1 and histone 3.3 constructs (RI: replication independent; RD replication dependent, TS testis specific).  
(B) CaSki and SiHa stable clones were cultivated for 4 days in the presence or absence (control) of 5 µM DAC. 
Histones were isolated incubating nuclear extracts in 0.2M sulfuric acid and subsequently in acetone. Then 
samples were dissolved in SDS sample buffer and analysed by Western blot. The clones expressing the Myc-
H3.1/H3.3 proteins were detected using a Myc-specific antibody. 
 
To investigate this hypothesis, stable clones from CaSki and SiHa cells expressing 
Myc-tagged-H3.1 or H3.3 variants under the control of a CMV promoter were generated. The 
sub-cloned cells were tested for Myc-H3.1 or Myc-H3.1 expression. Thereby, the histones 
were isolated by incubation of nuclear extracts in 0.2M sulfuric acid and precipitated in 
acetone. Subsequently, the Myc-tagged histones were detected in Western blot using an 
antibody against the Myc-tag. Different clones were analysed in both cell lines. Since the 
CMV promoter can be de novo methylated in stable cells, treatment with DAC was necessary 
in some clones to induce Myc-H3.3 protein expression. In order ensure equal Myc- H3.3 
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expression, independently of DAC treatment, the CaSki clone 3 (C-c3:H3.3) was selected 
(Figure 4.18B) for further experiments.  
 
4.6.1 Incorporation of Myc-H3.3 into the URR of HPV-16 after DAC 
treatment 
 
Clone 3 (C-c3:H3.3) expresses Myc-H3.3 independently of DAC treatment. In order to 
verify the functionality, and incorporation of the expressed histone variant into the HPV 
genomes, Chromatin Immunoprecipitations (ChIP) were performed.  
ChIP is a powerful method to identify in vivo interactions between proteins and 
specific DNA sequences (Orlando et al., 1997). Any chromatin-associated or DNA binding 
protein, including histones, can be analyzed, depending on which antibody is used. The initial 
step of this technique is the cross-linking of protein-protein and protein-DNA complexes in  
  
 
 
 
 
 
 
 
Figure 4.19 Incorporation of histone Myc-H3.3 variants into the URR of HPV-16 after DAC 
treatment in CaSki stable Myc-H3.3 clone (C-c3:H3.3).  
C-c3:H3.3 cells were cultivated for 4 days in the presence or absence (control) of 5 µM DAC. ChIP was carried 
out with 20 µg chromatin using an anti-Myc antibody and IgG control antibodies. The precipitated DNA was 
analysed by PCR using primers for the HPV-16 URR and E7. As a control (input) 20 µg chromatin was de-
cross-linked and this 1:100 diluted DNA was also used for PCR with HPV-16 URR and E7 primers. Input: 
control: DNA without immunoprecipitation from the same sample, IgG: control: immunoprecipitation with an 
unspecific antibody, Myc: immunoprecipitaion with the Myc-specific antibody. 
 
 
live cells with formaldehyde (Orlando et al., 1997). Thereby, C-c3:H3.3 cells treated with 
DAC and untreated controls were used. 
After cross-linking, the cells were lysed and subsequently the crude extracts were 
sonicated for shearing the DNA. DNA fragments up to 500 bp length were prepared. Myc-
H3.3 histones cross-linked to DNA were immunoprecipitated by an antibody recognizing the 
Myc-tagged part of the H3.3. Subsequently, the cross-linking in the presence of high salt was 
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reversed by incubation of the samples at 65°C over night. The purified DNA fragments were 
amplified by PCR using the HPV-16 URR1.1, URR1.2 and E7 primers.  
DAC treatment of C-c3:H3.3 cells induced a strong increase of incorporated Myc-
H3.3 into demethylated HPV genomes. The histone variants were detected in the URR region 
of the HPV-16. Comparison of the IgG control samples to the Myc-IP samples after DAC 
treatment unravels a clear incorporation of Myc-H3.3 to both the URR1.1 and URR1.2 
sequences. In control samples, Myc-H3.3, is incorporated only at lower levels (Figure 4.19). 
Interestingly, no incorporation was detectable for the E7 sequence. These results imply that 
Myc-H3.3 is predominantly incorporated into the HPV genome region that is important for 
transcriptional regulation (URR). The coding regions, in this case of E7, lack Myc-H3.3.  
Consequently, the inclusion of Myc-H3.3 in the URR of HPV-16 after DAC treatment 
in C-c3:H3.3 cells might induce the transcription of the oncogene E7. Therefore, E7 
expression in C-c3:H3.3 cells after DAC treatment was analysed. 
 
4.6.2 Expression of the histone variant Myc-H3.3 in CaSki cells 
increases E7 transcription after DAC treatment   
 
ChIP experiments with the stable CaSki clone:C-c3:H3.3 showed, that Myc-H3.3 is 
incorporated after DAC treatment in the HPV-16 URR. This incorporation may influence the 
transcriptional activity of demethylated HPV-16 copies. Gene activation was expected, since 
H3.3 is known to carry N-terminal modifications, which correlate with actively transcribed 
regions (Ahmand et al., 2002; McKittrick et al., 2004; Johnson et al., 2004; Chow et al., 
2005).  
In order to verify that H3.3 incorporation in the HPV-16 URR after DAC treatment 
indeed leads to an up-regulation of E7 transcription, Northern blot and quantitative PCR 
experiments were performed with both, parental CaSki cells and Myc-H3.3 expressing cells: 
C-c3:H3.3. A decrease of E7 expression was detected in CaSki cells after DAC treatment, as 
was shown in previous RT-PCR and qPCR data (Figure 4.12). In contrast, DAC treatment of 
C-c3:H3.3 cells leads to an up-regulation of E7. This was detected by qPCR and Northern 
blot. The qPCR data revealed approximately three fold induction of the oncogene E7 
expression in DAC treated compared to untreated clones. Analysis by Northern blot, using the 
whole HPV-16 genome for hybridisation, further verified the observed up-regulation. 
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Figure 4.20 Expression of the histone variant Myc-H3.3 in CaSki cells increases the E7 
transcription after DAC treatment.  
CaSki cells stable clones expressing Myc-H3.3 were cultivated for 5 days in the presence or absence (control) of 
5 µM DAC. (A) Northern Blot with radio labelled HPV-16 specific probe. (B) Q-PCR after RT-reaction with 1 
µg RNA (in 20 µl volume) and random primers followed by PCR using 1 µl from the RT-reaction and HPV-
16E7 and GAPDH primers. The results were normalized to GAPDH housekeeping amplification. 
 
(Figure 4.20). These results, from two different experimental approaches qPCR and Northern 
blot, showed that up-regulation of E7 in CaSki depends on the interplay of two epigenetic 
mechanisms. Demethylation of the HPV genomes, and incorporation of H3.3, both are 
required for HPV-16 transcriptional activation.  
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5 Discussion 
5.1 Effects of DAC treatment in CaSki cells at protein level           
5.1.1 Treatment of CaSki cells with DAC induces demethylation of the 
HPV-16 URR  
In order to investigate the mechanisms and factors involved in the re-activation of 
inserted HPV genomes during progression to cervical cancer, we used the cervical carcinoma 
cell line CaSki, which contains approximately 600 integrated HPV-16 genomes (Mincheva et 
al., 1987). Besides one locus on chromosome 14, where nascent HPV RNA was detected by 
tyramide-FISH, the other HPV copies are transcriptionally silenced by methylation (Van Tine 
et al., 2001). Therefore, DNA demethylation of the silent HPV-16 copies by DAC may mimic 
demethylation observed during progression to cervical cancer and provides an opportunity for 
the analysis of the epigenetic factors involved in the regulation of HPV-16 genomes.  
The methylation status the of HPV genomes was assessed by digestion of the genomic 
DNA with the methylation sensitive enzyme HhaI and subsequent PCR with primers specific 
for the CpG site at the nucleotide 7674, which is located 40 bp upstream from two binding 
sites of the transcription factor AP-1 (Figure 4.3.). This site was of particular interest since it 
is located within the enhancer region of the HPV-16 URR. Analysis of demethylation 
demonstrated a decrease of DNA methylation after DAC treatment of approximately 50% 
compared to the untreated samples (Figure 4.3.). Besides this CpG site the HPV-16 genome 
possesses in its URR altogether 11 CpG sites (Figure 4.1.). Previous analysis of DNA 
methylation of the HPV-16 URR by bisulphite treatment revealed that these CpG sites in 
CaSki cells are heavily methylated (Kalantari et al., 2004). In 2006, Rajeevan et al. performed 
a more sensitive analysis by pyrosequencing. This method enables the direct quantification of 
DNA methylation. This approach demonstrated that there are differences between the 
methylation status of each CpG. While the CpGs in the promoter region are methylated in 
96% of the integrated copies in CaSki cells, the specific CpG at the nucleotide 7674, which 
was analysed in our experimental setting, was methylated in 75% of the viral copies 
(Rajeevan et al., 2006).  
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5.1.2 DAC treatment in CaSki cells induces the down-regulation of the 
oncoprotein E7, which is mediated by calpains and proteasomal 
pathway 
Treatment of CaSki cells with DAC induced demethylation of HPV-16 copies (Figure 
4.3). DNA demethylation has been shown to re-induce transcription of silent genes 
(Magdinier et al., 2000; van der Velden et al., 2001). Hence, for detection of transcriptional 
re-activation, previous studies have focused on the detection of induced expression on mRNA 
level. Nevertheless, the actual amount of E7 oncoprotein after DAC treatment has never been 
analysed.  
Surprisingly, in the case of CaSki cells DAC treatment leads to a down-regulation of 
the E7 oncoprotein expression (Figure 4.4). Analysis of the mRNA amount revealed only a 
slight down-regulation after DAC treatment which cannot, however, fully account for the 
observed down-regulation on protein level (Figure 4.12). Hence, other mechanisms must be 
involved. This leads to the assumption that different effects are responsible for the E7 down-
regulation on protein level. One possible explanation for the E7 down-regulation is the 
involvement of previously methylated miRNA. In fact specific methylation of miRNA genes 
in tumor cells has been described recently (Saito et al., 2006). According to this report, DAC 
treatment led to an up-regulation of 17 out of 313 miRNAs. Hence, DAC treatment could 
have changed the miRNA expression pattern in CaSki cells. The new expressed miRNA may 
recognize E6/E7 mRNA in a not completely homologous manner, leading to translational 
inhibition and E7 protein down-regulation. However, also additional mechanisms may be 
involved in this process, because treatment of CaSki cells with DAC in presence of 
proteasomal and calpain inhibitor MG132 rescued E7 from degradation (Figure 4.4). Two 
different proteins have been described in the literature as involved in E7 proteasomal 
degradation: the ubiquitin ligase Skp2 (Oh et al., 2005) and, after IFN-γ induction, SOCS-1 
(Kamio et al., 2004). SOCS-1 has been described to be methylated in 50% of cervical 
carcinomas (Widschwendter et al., 2004). However, no increase of SOCS-1 in CaSki cells 
after DAC treatment was observed. These experiments imply that Skp2 or other proteins 
might be involved in the E7 proteasomal degradation after DAC treatment (Kamio et al., 
2004). In order to unravel new E7 interaction partners, mass spectrometry analyses were 
carried out after immunoprecipititaion with a highly specific mouse monoclonal E7 antibody 
(Figure 4.7.). Using this approach, calpains were identified as new potential interaction 
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partners (Figure 4.8.). While the ubiquitous calpain 1 was co-immunoprecipitated with E7 in 
both DAC treated and untreated samples, calpain 12 was only detected after DAC treatment. 
E7 has already been described to harbor a (Pro, Glu, Ser/Thr-rich) PEST domain, which is 
necessary for the interaction with IRF-9 (Antonsson et al., 2006). Since calpains are known to 
recognize their substrates by PEST domains as well as other regions (Saez et al., 2006), it was 
reasonable to assume that E7 could interact with calpains leading to its degradation. Although 
MG132 is a strong inhibitor of the proteasome, it olso blocks calpains. This suggests that 
calpains may be involved. To definitely clarify whether E7 is also degraded by calpains CaSki 
cells were treated with the specific calpain inhibitor ALLM. Under this conditions an 
accumulation of E7 was observed in the DAC exposed cells (Figure 4.9.), supporting the 
assumption that calpains are involved in E7 degradation. Nevertheless, inhibition of E7 
degradation was not as efficient as with MG132, indicating that both pathways may act 
together in this process. This is in agreement with a recent publication, where calpains can 
interact with E7 and thus contribute to E7 mediated pRb degradation (Suhrbier et al., 2007).  
 
5.1.3 E7 degradation after DAC treatment is also induced in HeLa and 
somatic hybrid cell lines 
Treatment with DAC did not change the E7 levels in SiHa cells, but led to a down-
regulation of the E7 oncoprotein in CaSki cells. In order to clarify, if this CaSki related 
phenotype is linked to a dominant or recessive genotype, hybrid cell lines were analysed. 
Furthermore, using these hybrids, it was possible to determine, if the observed degradation is 
specific only for HPV-16. Since CaSki cells have been established from a small intestine 
metastasis (Pattillo et al., 1977), these cells might harbor a specific genotype, which provides 
a background for the observed E7 down-regulation. To further investigate this hypothesis 
HeLa cells and somatic cell hybrids (Figure 4.5) were incubated with DAC. Subsequent 
Western blots revealed E7 protein down-regulation after DAC treatment in both parental lines 
and all somatic hybrid lines derived thereof (Figure 4.6). Interestingly, in CaSki X SiHa 
hybrids E7 was also degraded after DAC treatment suggesting that the CaSki genotype is 
dominant (Figure 4.6). Hence, these experiments demonstrate that the DAC induced E7 
degradation is a dominant mechanism and is independent of the virus type, since HPV-18E7 
was also down-regulated in HPV-18 positive HeLa cells after DAC treatment (Figure 4.6). 
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5.2 Identification of a novel interaction partner of E7: CARM1  
 
Besides the E7-calpain interaction, mass spectrometery (MS), also provided evidence 
that E7 can associate with CARM1 (Figure 4.8). E7 is known to interact with a variety of 
proteins in order to alter cellular mechanisms for ensuring progression through the cell cycle 
and proliferation (Figure 2.4). So far, the best studied interaction partner is pRb (Dyson et al., 
1998) but interactions with other proteins such as the transcription factor c-Jun (Antinore et 
al., 1996), Mi2 (Brehm et al., 1999), a member of the NURD complex and histone 
deacethylases (HDACs) (Brehm et al., 1999), have also been described.  
 In order to further validate the MS results endogenous E7-CARM1 interaction was 
verified by immunoprecipitating E7 and probing against CARM1 by Western blot. Following 
the E7-IP, a distinct band migrating near the heavy chain of E7 antibody was visualized 
corresponding to the size expected for CARM1 (Figure 4.10). This result was reproducible 
strengthening the conclusion that the identified interaction between endogenous E7 and 
CARM1 proteins is valid.  
Nevertheless, the functional role of the E7-CARM1 interaction needs to be 
determined. CARM1 is a strong activator of transcription (Bauer et al., 2003, El Messaoudi et 
al., 2006). This is due to its ability to methylate Lsy17 on histone H3 (Bauer et al., 2003). 
CARM1 co-activates several genes like cycline E1 (El Messaoudi et al., 2006) and nuclear 
receptor regulated genes (Chen et al., 1999). In addition to gene activation, a crosstalk 
between CBP histone acetyltransferase transcription factors and CARM1 was reported 
(Daujat et al., 2002). Besides chromatin modification, CARM1 is also involved in 
methylation with concomitant activation and stabilisation of proteins such as the 
transcriptional coactivator p/CIP (Naeem et al., 2006). The E7-CARM1 interaction might lead 
to recruitment of CARM1 to E7 regulated genes, for example Cdc25, resulting in their 
activation. Of particular interest is the idea that E7 might recruit CARM1 to the HPV 
enhancer for inducing its own transcription. This hypothesis can be analysed by ChIP for the 
CARM1 substrate Lys17me with primers specific for the HPV enhancer. Interestingly 
CARM1 is down-regulated after DAC treatment of CaSki cells (Figure 4.11). This may 
explain the slight E7 down-regulation at transcriptional level after DAC treatment (Figure 
4.12). 
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5.3 Effects of DAC treatment at transcriptional level in CaSki cells 
5.3.1 Treatment with DAC induces a slight reduction of HPV-16E7 
transcription 
Analysis of the E7 oncoprotein expression on protein level showed that E7 is down-
regulated after DAC treatment of CaSki cells. Additional analysis of the E7 transcription also 
revealed a slight reduction after DAC treatment in CaSki cells on mRNA level (Figure 4.12.). 
This was an unforeseen result, since the enhancer region of at least half of the HPV genomes 
was demethylated and therefore re-activation of viral transcription was expected. In 
accordance with our data a recently published report described only a minimal induction of 
E7 transcription after DNA demethylation by hydralyzine, in CaSki cells. Furthermore, 
analysis of E7 transcription in cervical cancer patients treated with hydralazine revealed a 
down-regulation of the oncogene expression (de la Cruz-Hernández et al., 2007). This was 
also observed in the somatic cell hybrids and parental HeLa cells (Fig 3.17). 
 In order to investigate the reason for lack of viral transcriptional induction, the AP-1 
composition in CaSki and SiHa cells after DAC treatment was analysed. AP-1 is an essential 
transcription factor for the initiation of HPV transcription (Butz and Hoppe-Seyler, 1993). 
Here the composition of the AP-1 family members is known to play a crucial role for the 
induction of HPV transcription. c-Jun/c-Fos are known as strong activators, in contrast to c-
Jun/Fra-1 dimers (Rösl et al., 1997; Soto et al., 1999). Three different AP-1 binding sites are 
present in the upstream regulatory region (URR) of the HPV-16. Interestingly, monitoring 
AP-1 expression by RT-PCR and Western blot, a strong up-regulation of c-Jun, Fra-1 and 
JunD was detected in CaSki, but not in SiHa cells after DAC treatment (Figure 4.13). In 
addition, expression of c-Fos, the activator of HPV transcription, could still not be detected in 
CaSki cells. To further characterize the AP-1 composition in CaSki cells after DAC treatment 
EMSA experiments were carried out. The results revealed that the predominant AP-1 
complexes in CaSki cells consist of c-Jun/Fra-1 dimers, which bind both to AP-1 consensus 
and HPV-16AP-1 sequences (Figures 3.15/3.16). This AP-1 composition has been shown to 
attenuate AP-1 activity leading to a reduction in the transcriptional activity (Soto et al., 1999). 
Therefore, this kind of AP-1 complex may account for the absence of gene induction, leading 
even to a slight down-regulation in the E6/E7 transcription. The observed increase of c-Jun, 
JunD and Fra-1 in DAC treated CaSki cells was not due to activation of the stress signalling 
pathway mediated by JNK or p38, since no phophorylation of these MAPK could be detected 
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(Figure 4.14.). However, the up-regulation may be due to a positive feedback loop since Fra-1 
and c-Jun harbour AP-1 sites in their enhancer regions (Angel et al., 1988, Adiseshaiah et al., 
2005). Another interesting possibility is the induced up-regulation of these AP-1 family 
members by demethylation. The transcriptional initiation regions of all three up-regulated 
genes harbor a high number of CpG sites. In normal cells, these CpGs are unmethylated, 
ensuring the typical rapid transcriptional initiation of immediate-early genes. CaSki cells are 
polyploid harbouring 3 copies of chromosomes 1 and 11 where the genes for c-jun and Fra-1, 
respectively are located (Jesudasan et al., 1995). Therefore, it would be interesting to find out 
if these additional chromosomes are transcriptionally active or if the additional c-jun or fra-1 
genes are silenced by methylation. In the latter case treatment with DAC might induce gene 
re-expression leading to up-regulation of the proteins.  
 
5.4 Demethylation of the HPV genomes serves as a prerequisite for 
transcriptional activation, but additionally requires the 
incorporation of H3.3 into the URR of HPV-16  
 
Chromatin modifications are essential epigenetic marks for transcriptional control. 
(Kouzarides, 2007). In the last few years another level of regulation has become evident, 
namely the importance of histone variants in the acquisition of different histone marks. The 
histone variants H3.1 and H3.3 have been the particular focus of investigation (Ahmand et al., 
2002; McKittrick et al., 2004; Johnson et al., 2004). In order to analyse the influence of these 
histone variants in the transcriptional regulation of HPV genomes, stable cell lines from 
CaSki cells expressing Myc-tagged H3.1 or H3.3 have been generated and analysed (Figure 
4.18). This experimental approach provides the first demonstration that in CaSki cells, despite 
demethylation of HPV genomes by DAC, the incorporation of Myc-H3.3 into the 
nucleosomes of HPV-16 URR was necessary for re-activation of silent HPV copies. Only in 
combination these epigenetic changes, led to a strong activation of the HPV-16E7 expression 
(Fig. 3.20).  
Three major differences have been characterized between the histone 3 variants H3.1 
and H3.3. Firstly, H3.3 is incorporated into nuclesomes at transcriptionally active regions and 
is thought to exchange H3.1 at these sites after gene activation (McKittrick et al., 2004, Hake 
and Allis, 2006). Secondly, H3.3 is incorporated throughout the cell cycle in contrast to H3.1 
which is strictly incorporated into chromatin only during replication (Ahmad and Henikoff 
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2002). Finally, the h3.3 gene is expressed throughout the cell cycle, whereas h3.1 is expressed 
only during the DNA synthesis phase (Sarma and Reinberg, 2005). Previous studies have 
concluded that H3.3 incorporation at active loci not only marks transcriptionally active genes, 
but deposition of H3.3 might maintain cellular memory of active transcription states during 
mitosis (McKittrick et al., 2004). Interestingly, euchromatin is synthesised early in the S-
phase in contrast to heterochromatin which is replicated late (Gilbert, 2001; Gilbert, 2002). 
Furthermore, due to the delay in synthesis there is more H3.3 than H3.1, at the beginning of 
the S-phase where the euchromatin is replicating. Hence, more H3.3 is incorporated into the 
nucleosomes whereas predominantly H3.1 is incorporated during the late S-phase, when the 
heterochromatin is duplicated (Ahmad et al., 2002).   
In order to analyse the Myc-H3.3 expression in the stable cell lines, histones were 
isolated and the amount of Myc-H3.3 was detected by Western blot using an anti-Myc 
antibody (Fig.3.18). This experiment revealed that not all stable CaSki clones expressed and 
incorporated the recombinant Myc-H3.3 in the absence of DAC. This was apparently due to 
the CMV promoter which drives the ectopic transcription of Myc-H3.1 or Myc-H3.3 and is 
known to potentially become silenced by methylation when inserted in the host genome. The 
experiments presented here were carried out with the Myc-H3.3 clone3 from CaSki cells, 
which expresses the tagged histone in the absence of DAC. This clone does not differ in its E7 
expression levels from the CaSki parental cell line. This implicates that the expression of 
Myc-H3.3 alone is not sufficient for re-activation of the silenced HPV-16 genomes in CaSki 
cells (Fig 3. 20). 
After quantification of the Myc-H3.3 amount in the CaSki cell clone 3 the 
incorporation of the Myc-H3.3 into the HPV genomes was analysed by ChIP. Interestingly, 
the recombinant Myc-H3.3 protein is only minimally incorporated into the chromatin in 
methylated HPV genomes in the absence of DAC (Fig. 3.19.). This might be due to the late 
replication of the methylated genomes, which implies preferential H3.1 incorporation (Hake 
and Allis, 2006). In addition, the methylated HPV genomes should have a close chromatin 
structure, which did not favour histone exchange.  
For monitoring the effects of DNA demethylation in addition to Myc-H3.3 expression, 
the Myc-H3.3 clone 3 from CaSki cells was treated with DAC. Analysis of E7 transcription 
revealed that E7 mRNA was up-regulated after treatment with DAC (Figure 4.20.). 
Subsequent ChIP analysis for detection of incorporation of Myc-H3.3 at the promoter and 
enhancer regions of the HPV genomes showed an enhanced incorporation of the variant after 
DAC treatment compared to the untreated clone cells (Figure 4.19.). Taking together, these 
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experiments suggest that DAC treatment alone was not sufficient for re-activation of the silent 
HPV genomes. However, in combination with stable expression of the histone Myc-H3.3, 
gene silencing can be reverted and the HPV copies obtain the transcriptionally active state. 
The opening of the chromatin by demethylation favours Myc-H3.3 incorporation at the 
promoter and enhancer region. Hence, the particular combination of DNA demethylation and 
incorporation of a histone variant were able to establish a chromatin state which lacks 
repressive marks leading to the re-expression of the silent HPV copies in Myc-H3.3 clones. 
Both epigenetic marks, histone modifications and DNA methylation, are strongly influenced 
by and tightly regulate each other (Fahrner et al., 2002). Experiments in Arabidopsis thaliana 
have shown that a decrease in DNA methylation, as observed after DAC treatment in CaSki 
cells, does not directly cause loss of repressive marks, such as histone 3 lysine 9 methylation 
(H3K9me). Whereas reactivation of transcription is accompanied by loss of the H3K9 marks 
(Johnson et al., 2002). However, another study in bladder cancer cells reported a regional 
induction of chromatin remodelling after DAC treatment (Nguyen et al., 2002). The results of 
these studies, combined with the results presented here, lead to the proposal that although 
DNA methylation and chromatin remodelling influence each other, the outcome for a gene 
reactivation depends on the particular structure of the heterochromatin. Tumor-suppressor 
genes can be silenced in cancer, but they are usually located in euchromatin regions, which 
become silent by DNA methylation predominately at the promoters of the respective genes 
and are then referred to as facultative heterochromatin regions (Ehrlich, 2002; McGarvey et 
al., 2006). These regions can be reversed by DNA demethylation relatively easier than regions 
which are incorporated in late replicating heterochromatin or constitutive heterochromatin 
(Shafer and Priest, 1984). Our data suggest that the silent HPV genomes in CaSki cells could 
be predominantly located within late replicating highly condensed constitutive 
heterochromatin, which needs both DNA demethylation and repressive histone marks 
remission for its reactivation.  
In conclusion, the results presented here can be summarized by the following model 
Figure 5.1): The silent HPV genomes in CaSki cells are integrated in late replicating 
constitutive heterochromatin domains. Therefore DNA demethylation by DAC is not 
sufficient for altering the histone repressive marks, which in turn does not allow the re-
expression of the HPV-16 genomes. Furthermore, the up-regulation of the AP-1 family 
members such as Fra-1, c-Jun and JunD after DAC treatment leads to an accumulation and 
enhanced binding of AP-1 complexes, which conteract transcription from the already active 
HPV genomes. This may lead to a slight down-regulation of the E7 expression at mRNA 
Discussion_______________________________________________________________ 
 
92 
level. In contrast, the expression of Myc-H3.3 in CaSki clone 3 in the absence of DAC, led to 
a very inefficient incorporation of Myc-H3.3. Since under these conditions the repressive 
chromatin state generated by methylation and remaining histone marks. Upon demethylation 
of the HPV genomes by DAC and the enhanced exchange of Myc-H3.3 the repressive marks 
are significantly reduced. The incorporation of Myc-H3.3 recruits transcription initiation 
complexes. This leads to transcriptional initiation, which subsequently induces a positive 
feed-back loop leading to an enhanced incorporation of Myc-H3.3 which in turn harbours 
positive marks, and therefore increases transcriptional activity (Figure 5.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Schematic overview of the observed mechanism for the re-activation of silenced HPV-16 
genomes  
CaSki cells harbour silenced HPV-16 genomes, with methylated DNA and histones (H3) with negative marks for 
repression of transcription. After DAC treatment, the DNA is demethylated but the nucleosomes still harbour 
histones with repressive marks. In CaSki clones expressing H3.3, this histone variant, is incorporated into the 
HPV URR after DAC treatment. Now the histones (Myc-H3.3) harbour positive marks and the transcritption of 
E7 is induced, leading to the up-regulation of E7 mRNA. 
 
 
 
- methylated DNA
- nucleosomes with histones H3 carrying
repressive marks for transcription 
 no E7 expression
- demethylated DNA
- nucleosomes with histones H3 carrying
repressive marks for transcription
 no E7 experssion
- demethylated DNA
- nucleosomes with histones H3.3 carrying
activating marks for transcription
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A. silenced HPV-16 genomes
B. silenced HPV-16 genomes after DAC treatment
C. re-activated HPV-16 genomes after DAC treatment and H3.3 incorporation
= CpGme = repressive mark = activating mark
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6 Abbreviations and Reference List 
6.1 Abbreviations 
5-azycytidine          AC 
N-acetyl-leucyl-leucyl-methionine, calpain inhibitor   ALLM 
activator protein 1         AP-1 
activating transcription factor      ATF 
antioxidant-response elements       AREs 
basic leucin zipper domain        bZIP 
breast cancer 1         BRCA1 
Chromatin Immunoprecipitations       ChIP 
cAMP-respose element        CRE 
chromatin assembly factor        CAF-1 
CaSki clone 3 expressing Myc-H3.3      C-c3:H3.3 
coactivator-associated arginine methyltransferase 1    CARM-19 
conserved region         CR 
cytosines located 5´ to guanosine      CpGs 
colony stimulating factor-1 receptor      CSFR 
5-aza-2’-deoxycytidine       DAC 
DNA methyltranferase1       DNMT1. 
extracellular-regulated kinase       ERK 
epidermal growth factor receptor       EGFR 
electrophoretic mobility shift assays      EMSA 
immediate early genes        IE 
immunoprecipitation         IP 
folate receptor         FR 
glucocorticoid receptor        GR 
heterochromatin associated protein 1      HP1 
Histone acetyltransferases        HAT 
Histone deacetylases         HDAC 
H3 lysine 9 acetylation       H3K9ac 
H3 lysine 36 methylation        H3K36me 
H3 lysine 79 methylation       H3K79me 
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H3 lysine 9 methylation        H3K9me 
phosphorylation of H3 at serine 10       H3S10phos 
histone methyltransferase        HMT 
Histone variant 3.3        H3.3 
Histone 3.1         H3.1 
Human papilloma viruses        HPV 
human immunodeficiency virus       HIV 
histone cell cycle regulation defective homolog A     HIRA 
c-Jun N-terminal kinase        JNK 
Mixed-lineage leukaemia       MLL1 
methyl-CpG-binding –protein 2       MeCP2 
MAF recognition elements       MAREs 
Mitogen activated protein kinases      MAPK 
Mass spectrometry        MS 
MAP-Kinase-Kinase-Kinases       MAPKKK 
MAP-Kinase-Kinases       MAPKK 
musculoaponeurotic fibrosarcoma       MAF 
proteasomal and calpain inhibitor      MG132 
Recombinant Myc tagged Histone H3.3     Myc-H3.3 
nuclear factor 1         NF1 
octamer binding factor 1        OCT1 
Polymerase chain reaction       PCR 
antioxidant pyrrolidine-dithiocarbamate      PDTC 
Papilloma viruses         PV 
(Pro, Glu, Ser/Thr-rich) domain      PEST 
plant homeo domain         PHD 
quantitative PCR        qPCR 
replication dependent        RD 
retinoblastoma protein 1        pRb 
Reverse Transcription       RT 
Enhancer-of-zeste E(z), Trithorax (Trx)      SET 
suppressor of cytokine signaling       SOCS-1 
Suppressor of variegation 3-9       Su(var)3-9 
steroidogenic factor 1        SF1 
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tumor necrosis factor alpha       TNF-alpha 
12-O-tetradecanoylphorbol-13-acetate     TPA 
TPA response element        TRE 
trithorax          Trx 
transcription enhancer factor 1       TF1 
TATA-box binding protein       TBP 
upstream regulatory region        URR 
Vascular Endothelial Growth Factor-D      VEGF-D 
Western blot         WB 
Yin Yang 1          YY1 
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